Nutra Pharma (NPHC) 10-Q 14 May 21 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	May 14, 2021
Cover [Abstract]
Entity Registrant Name	NUTRA PHARMA CORP
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		7,243,419,714
Amendment Flag	false
Entity Central Index Key	0001119643
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-32141
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	91-2021600
Entity Address, Address Line One	1537 NW 65th Avenue
Entity Address, City or Town	Plantation
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33313
City Area Code	954
Local Phone Number	509–0911
Entity Interactive Data Current	No

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash
Accounts receivable	41,752	17,065
Inventory	36,229	35,302
Prepaid expenses and other current assets	48,848	63,000
Total current assets	126,829	115,367
Property and equipment, net	7,475	10,500
Operating lease right-of-use assets	220,532
Security deposit	15,550	15,550
Total assets	370,386	141,417
Current liabilities:
Accounts payable	551,016	475,409
Accrued expenses	897,216	831,849
Accrued payroll due to officers	1,205,393	1,050,993
Accrued interest to related parties	154,871	141,808
Due to officer	139,722	186,497
Derivative warrant liability	1,171	1,468
Other debt, net of discount, current portion	4,834,104	3,338,576
Operating lease obligations, current portion	71,013
Total current liabilities	7,854,506	6,026,600
Promissory note, less current portion		51,410
Convertible note, less current portion	479,886
Operating lease obligations, less current portion	162,679
Total liabilities	8,497,071	6,078,010
Stockholders' deficit:
Preferred stock, $0.001 par value, 20,000,000 shares authorized: 3,000,000 Series A Preferred shares issued and outstanding at September 30, 2019 and December 31, 2018	3,000	3,000
Common stock, $0.001 par value, 8,000,000,000 shares authorized: 5,076,746,111 and 4,046,746,110 shares issued and outstanding at September 30, 2019 and December 31, 2018	5,076,746	4,046,746
Additional paid-in capital	50,622,133	51,286,503
Accumulated deficit	(63,828,564)	(61,272,842)
Total stockholders' deficit	(8,126,685)	(5,936,593)
Total liabilities and stockholders' deficit	$ 370,386	$ 141,417

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018	Dec. 30, 2018
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	8,000,000,000	8,000,000,000
Common stock, shares issued	5,076,746,111	4,046,746,110
Common stock, shares outstanding	5,076,746,111	4,046,746,110
Series A Preferred Stock [Member]
Preferred stock, shares issued	3,000,000		3,000,000
Preferred stock, shares outstanding	3,000,000		3,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Net sales	$ 41,962	$ 43,966	$ 93,499	$ 104,323
Cost of sales	(6,495)	(37,409)	(25,894)	(58,338)
Gross profit	35,467	6,557	67,605	45,985
Operating expenses:
Selling, general and administrative - including stock based compensation of $7,500 and $30,000 for the three months ended September 30, 2019 and 2018, and $64,000 and $40,000 for the nine months ended September 30, 2019 and 2018, respectively	270,649	860,808	879,571	1,573,541
Total operating expenses	270,649	860,808	879,571	1,573,541
Loss from operations	(235,182)	(854,251)	(811,966)	(1,527,556)
Other income (expenses)
Rental Income		525		525
Interest expense	(52,918)	(262,891)	(187,895)	(695,763)
Interest expense to related parties	(4,499)	(3,998)	(13,063)	(11,609)
Change in fair value of convertible notes and derivatives	(187,823)	192,800	(1,592,351)	(1,790,064)
Gain (Loss) on settlement of debt and accounts payable, net	(6,650)	(40,100)	49,553	728,223
Total Other income (expenses)	(251,890)	(113,664)	(1,743,756)	(1,768,688)
Loss before income taxes	(487,072)	(967,915)	(2,555,722)	(3,296,244)
Provision for income taxes
Net loss	$ (487,072)	$ (967,915)	$ (2,555,722)	$ (3,296,244)
Net loss per share - basic and diluted	$ 0	$ 0	$ 0	$ 0
Weighted average number of shares outstanding during the year - basic and diluted	5,057,898,285	3,709,263,480	4,575,964,059	2,880,009,357

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Stock based compensation	$ 7,500	$ 30,000	$ 64,000	$ 40,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 3,000	$ 2,032,234	$ 49,942,719	$ (57,388,147)	$ (5,410,194)
Balance, shares at Dec. 31, 2017	3,000,000	2,032,233,701
Issuance of common stock in exchange for services to consultants		$ 100,000	20,000		120,000
Issuance of common stock in exchange for services to consultants, shares		100,000,000
Common stock issued for debt modification and penalty		$ 127,782	41,953		169,735
Common stock issued for debt modification and penalty, shares		127,782,409
Common stock issued for conversion of debt		$ 1,399,680	1,034,772		2,434,452
Common stock issued for conversion of debt, shares		1,399,680,000
Common stock issued for settlement of accounts payable and debt		$ 335,300	12,750		348,050
Common stock issued for settlement of accounts payable and debt, shares		335,300,000
Common stock issued with Debt--Debt discount		$ 14,250	8,115		22,365
Common stock issued with Debt--Debt discount, shares		14,250,000
Beneficial conversion features			246,913		246,913
Net loss				(3,296,244)	(3,296,244)
Balance at Sep. 30, 2018	$ 3,000	$ 4,009,246	51,307,222	(60,684,391)	(5,364,923)
Balance, shares at Sep. 30, 2018	3,000,000	4,009,246,110
Balance at Jun. 30, 2018	$ 3,000	$ 3,241,052	51,367,587	(59,716,476)	(5,104,837)
Balance, shares at Jun. 30, 2018	3,000,000	3,241,052,167
Common stock issued for debt modification and penalty		$ 56,161	13,004		69,165
Common stock issued for debt modification and penalty, shares		56,160,940
Common stock issued for conversion of debt		$ 559,233	(39,669)		519,564
Common stock issued for conversion of debt, shares		559,233,003
Common stock issued for settlement of accounts payable and debt		$ 147,800	(43,500)		104,300
Common stock issued for settlement of accounts payable and debt, shares		147,800,000
Common stock issued with Debt--Debt discount		$ 5,000	(1,200)		3,800
Common stock issued with Debt--Debt discount, shares		5,000,000
Beneficial conversion features			11,000		11,000
Net loss				(967,915)	(967,915)
Balance at Sep. 30, 2018	$ 3,000	$ 4,009,246	51,307,222	(60,684,391)	(5,364,923)
Balance, shares at Sep. 30, 2018	3,000,000	4,009,246,110
Balance at Dec. 31, 2018	$ 3,000	$ 4,046,746	51,286,503	(61,272,842)	(5,936,593)
Balance, shares at Dec. 31, 2018	3,000,000	4,046,746,110
Issuance of common stock in exchange for services to consultants		$ 135,000	(105,000)		30,000
Issuance of common stock in exchange for services to consultants, shares		135,000,000
Common stock issued for debt modification and penalty		$ 22,000	(14,300)		7,700
Common stock issued for debt modification and penalty, shares		22,000,000
Common stock issued for conversion of debt		$ 750,000	(475,000)		275,000
Common stock issued for conversion of debt, shares		750,000,000
Common stock issued with Debt--Debt discount		$ 42,000	(29,617)		12,383
Common stock issued with Debt--Debt discount, shares		42,000,001
Common stock issued for settlement of debt		$ 81,000	(48,600)		32,400
Common stock issued for settlement of debt, shares		81,000,000
Beneficial conversion features			8,147		8,147
Net loss				(2,555,722)	(2,555,722)
Balance at Sep. 30, 2019	$ 3,000	$ 5,076,746	50,622,133	(63,828,564)	(8,126,685)
Balance, shares at Sep. 30, 2019	3,000,000	5,076,746,111
Balance at Jun. 30, 2019	$ 3,000	$ 5,038,246	50,648,088	(63,341,492)	(7,652,158)
Balance, shares at Jun. 30, 2019	3,000,000	5,038,246,111
Common stock issued for debt modification and penalty		$ 18,500	(11,850)		6,650
Common stock issued for debt modification and penalty, shares		18,500,000
Common stock issued with Debt--Debt discount		$ 20,000	(14,105)		5,895
Common stock issued with Debt--Debt discount, shares		20,000,000
Net loss				(487,072)	(487,072)
Balance at Sep. 30, 2019	$ 3,000	$ 5,076,746	$ 50,622,133	$ (63,828,564)	$ (8,126,685)
Balance, shares at Sep. 30, 2019	3,000,000	5,076,746,111

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (487,072)	$ (967,915)	$ (2,555,722)	$ (3,296,244)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense			40,789	498,470
Accrued interest expense for amount due to officer			4,990
Gain on settlement of debt and accounts payable	6,650	40,100	(49,553)	(728,223)
Depreciation	815	1,105	3,025	4,858
Stock-based compensation	7,500	30,000	64,000	40,000
Stock-based loan modification cost				198,865
Change in fair value of convertible notes and derivatives	187,823	(192,800)	1,592,351	1,790,064
Amortization of loan discount			81,564	314,219
Amortization of operating lease right-of-use assets			60,643
Changes in operating assets and liabilities:
Increase in accounts receivable			(27,476)	(1,763)
Increase in inventory			(927)	(21,644)
Increase in prepaid expenses and other current assets			(19,848)	(19,257)
Increase in accounts payable			75,607	235,236
Increase in accrued expenses			175,639	144,007
Increase in accrued payroll due to officers			154,400
Decrease in deferred revenue				(22,490)
Increase in accrued interest to related parties			13,063
Decrease in operating lease obligations			(47,483)
Net cash used in operating activities			(434,938)	(863,902)
Cash flows from financing activities:
Loans from officer			5,000	107,100
Repayment of officers loans			(94,765)	(141,070)
Proceeds from convertible notes			578,283	941,800
Repayment of convertible notes			(11,500)	(3,000)
Repayments of other notes payable			(42,080)	(26,769)
Net cash provided by financing activities			434,938	878,061
Net increase in cash				14,159
Cash - beginning of period
Cash - end of period		$ 14,159		14,159
Supplemental Cash Flow Information:
Cash paid for interest				5,425
Cash paid for income taxes
Non cash Financing and Investing:
Note and stock issued in settlement of notes and accounts payable			32,400	348,050
Shares issued to satisfy debt			275,000	2,434,452
Discounts on notes payable			20,530	22,365
Debt discount for beneficial conversion features				246,913
Right-of-use asset due to adoption of ASC 842			281,175
Operating lease liabilities due to adoption of ASC 842			281,175
Restatement of accrued interest to debt			$ 66,460

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation. Reclassification of Prior Year Presentation Reclassification occurred to certain prior year amounts in order to conform to the current year classifications. The reclassifications have no effect on the reported net loss. Restatement of Prior Period Presentation Certain prior period amounts have been restated. Restatements have been made for the three and nine months ended September 30, 2018 to correct the change in the fair value of convertible notes and to record a gain on settlement of debt and accounts payable. As a result of these changes, the following occurred: 1. Net loss for the three and nine months ended September 30, 2018 decreased by $0 and $3,110,017, respectively ($0.00 per share) (see table below). 2. At September 30, 2018, there was no change to total stockholders’ deficit but additional paid-in capital and accumulated deficit decreased by $3,110,017. 3. Certain amounts in cash flows from operating activities were updated for the nine months ended September 30, 2018, but there was no change to the total net cash used in operating activities in the Unaudited Condensed Consolidated Statements of Cash Flows. For the Nine Months Ended September 30, 2018 Amounts Restated Amounts Previously Reported Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (1,790,064 ) $ (4,151,435 ) $ 2,361,371 Gain(loss) on settlement of debt and accounts payable 728,223 (20,423 ) 748,646 Net effect of restatement on net loss $ 3,110,017 Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $63,828,564 at September 30, 2019. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $7,727,677 and a stockholders’ deficit of $8,126,685 at September 30, 2019. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895 (See Note 12). During April and June 2020, we obtained a loan in the amount of $154,900 from the SBA under its Economic Injury Disaster Loan assistance program. We intended to use the proceeds primarily for working capital purpose (See Note 12). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the development of widespread testing or a vaccine. Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and warrant liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers On January 1, 2018, we adopted Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon delivery of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record shipping and handling costs incurred within revenue. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivables. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. Management believes that the receivables are fully collectable. Therefore, no allowance for doubtful account was deemed to be required at September 30, 2019 and December 31, 2018. Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at September 30, 2019 and December 31, 2018, and increased the reserve on supplier advances for future venom purchases included in the prepaid expenses and other current assets by $0 and $47,757, respectively. At September 30, 2019 and December 31, 2018, the total valuation allowance for prepaid venom is $200,911. Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended September 30, 2019, there were two customers that accounted for 62% and 13% of the total revenues. For the three months ended September 30, 2018, there was one customer that accounted for 35% of the total revenues. For the nine months ended September 30, 2019, there were two customers that accounted for 14% and 55% of the total revenues. For the nine months ended September 30, 2018, there was one customer that accounted for 27% of the total revenues. As of September 30, 2019 and December 31, 2018, 68% and 84% of the accounts receivable balance are reserves due from two payment processors. Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” (Topic 842), as amended (“ASC Topic 842”). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC Topic 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC Topic 842), therefore there was no change in accounting treatment required. For comparability purposes, the Company will continue to comply with the previous disclosure requirements in accordance with the existing lease guidance and prior periods are not restated. The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. For periods prior to the adoption of ASC Topic 842, the Company recorded rent expense based on the term of the related lease. The expense recognition for operating leases under ASC Topic 842 is substantially consistent with prior guidance. As a result, there are no significant differences in our results of operations presented. The impact of the adoption of ASC 842 on the balance sheet was: As reported December 31, 2018 Adoption of ASC 842 - increase (decrease) Balance January 1, 2019 Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592 Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Property and Equipment and Long-Lived Assets Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. Income Taxes The Company recorded no income tax expense for the nine months ended September 30, 2019 and 2018 because the estimated annual effective tax rate was zero. As of September 30, 2019, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Loss Per Share Net loss per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share September 30, 2019 September 30, 2018 Options and warrants 8,500,000 12,600,000 Convertible notes payable 10,215,644,748 3,260,602,785 Total 10,224,144,748 3,273,202,785 Recent Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at September 30, 2019 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at September 30, 2019 and December 31, 2018: Fair Value Measurements at September 30, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,171 $ - $ - $ 1,171 Convertible notes at fair value $ 3,103,172 $ - $ - $ 3,103,172 Fair Value Measurements at December 31, 2018 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,468 $ - $ - $ 1,468 Convertible notes at fair value $ 1,156,341 $ - $ - $ 1,156,341 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the nine months ended September 30, 2019 and the year ended December 31, 2018: Description September 30, 2019 December 31, 2018 Beginning balance $ 1,468 $ 5,903 Total gain included in earnings (1) (297 ) (4,435 ) Ending balance $ 1,171 $ 1,468 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 1.75% to 2.81% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 256%-335% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at September 30, 2019 and December 31, 2018: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Conversion Price % of stock price for look-back period Look-back September 30, 2019 $ 1,159,883 8%-20% 20%-24% 15.95-27.95 $0.00012-$0.000165 50%-60% 3 to 25 Days December 31, 2018 $ 1,340,026 8%-12% 18%-20% 25.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2019 and the year ended December 31, 2018: Description September 30, 2019 December 31, 2018 Beginning balance $ 1,156,341 $ 1,925,959 Purchases and issuances 629,183 472,029 Day one loss on value of hybrid instrument (1) 788,230 2,021,041 Loss from change in fair value (1) 804,418 130,344 Gain on settlement - (958,581 ) Conversion to common stock (275,000 ) (2,434,451 ) Ending balance $ 3,103,172 $ 1,156,341 (1) The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventories	3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At September 30, 2019 and December 31, 2018, inventories were as follows: September 30, 2019 December 31, 2018 Raw Materials $ 34,433 $ 33,431 Finished Goods 1,796 1,871 Total Inventories $ 36,229 $ 35,302

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at September 30, 2019 and December 31, 2018: September 30, 2019 December 31, 2018 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (208,558 ) (205,533 ) Property and equipment, net $ 7,475 $ 10,500 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At September 30, 2019, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the nine months ended September 30, 2019 and 2018 was $3,025 and $4,858, respectively, and $815 and $1,105 for the three months ended September 30, 2019 and 2018, respectively.

Due to_from Officer

Due to/from Officer	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Due to/from Officer	5. DUE TO/FROM OFFICER At September 30, 2019, the balance due to our President and CEO, Rik Deitsch, is $139,722, which is an unsecured demand loan that bears interest at 4%. During the nine months ended September 30, 2019, we advanced $94,765 to and collected $5,000 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $4,990 and is included in the due to officer account. At December 31, 2018, the balance due to our President and CEO, Rik Deitsch, is $186,497, which is an unsecured demand loan that bears interest at 4%. . During the nine months ended September 30, 2018, we advanced $141,070 to and collected $107,100 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $7,674 and is included in the due to officer account. The Company has fully reserved receivables from companies owned by the Company’s CEO. The reserve was $543,470 and $505,470 as of September 30, 2019 and December 31, 2018. The increase in the reserve during the nine months ended September 30, 2019 was due to advances of $38,000 made to a Company owned by the CEO.

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt	6. DEBTS Debts consist of the following at September 30, 2019 and December 31, 2018: September 30, 2019 December 31, 2018 Note payable– Related Party (Net of discount of $600 and $2,400, $ 13,800 $ 12,000 Notes payable – Unrelated third parties (Net of discount of $11,895 1,411,308 1,469,690 Convertible notes payable – Unrelated third parties (Net of discount of 819,226 751,955 Convertible notes payable, at fair value (Net of discount of $33,516 and $0, respectively) (4) 3,069,656 1,156,341 Ending balances 5,313,990 3,389,986 Less: Long-term portion-Notes payable-Unrelated third parties $ (- ) $ (51,410 ) Less: Long-term portion-Convertible Notes payable-Unrelated third parties (479,886 ) - Current portion $ 4,834,104 $ 3,338,576 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At September 30, 2019 and December 31, 2018, we owed this director accrued interest of $154,871 and $141,808. The interest expense for the nine-months ended September 30, 2019 and 2018 was $13,063 and $11,609, respectively, and $4,499 and $3,998 for the three-months ended September 30, 2019 and 2018, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At September 30, 2019 and December 31, 2018, the principal balance of the loan was $13,800 and $12,000, net of debt discount of $600 and $2,400, respectively. The Note was settled in June 2020. (2) At September 30, 2019 and December 31, 2018, the balance of $1,411,308 and $1,469,690 net of discount of $11,895 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At September 30, 2019 and December 31, 2018, we owed principal balance of $168,135 and $192,974, and accrued interest of $48,213 and $40,033, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 11) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At September 30, 2019 and December 31, 2018, the accrued interest is $3,499 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At September 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $46,901 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At September 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $40,100 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018.The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. The note is in default and negotiation of settlement. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the nine months ended September 30, 2019 and 2018 was $3,616 and $2,765, respectively. The debt discount at September 30, 2019 and December 31, 2018 is $0 and $3,616. During September 2019, the Notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,895(See Note 7) and recorded as a debt discount that was amortized over the life of the note. The Note is in default and negotiation of settlement. At September 30, 2019 and December 31, 2018, the principal balance is $333,543 and $282,983, and the accrued interest is $4,670 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In January 2019, the principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). The remaining note of $15,000 was assigned to an unrelated third party and is in negotiation of settlement. At September 30, 2019 and December 31, 2018, the principal balance is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At September 30, 2019 and December 31, 2018, the accrued interest is $36,400 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At September 30, 2019 and December 31, 2018, the accrued interest is $2,892 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively. The monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid a total of $34,976 during the year ended 2018 and $23,080 during the nine months ended September 30, 2019. At September 30, 2019 and December 31, 2018, the principal balance is $112,346 and $135,426. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At September 30, 2019 and December 31, 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the nine months ended September 30, 2019 and 2018 was $6,000 and $6,000, respectively. The debt discount at September 30, 2019 and December 31, 2018 is $6,000 and $6,000, respectively. Repayments of $1,500 and $7,000 have been made during 2017 and 2018, respectively. During the nine months ended September 30, 2019, repayment of $3,000 has been made. The Note is under personal guarantee by Mr. Deitsch. At September 30, 2019 and December 31, 2018, the principal balance of the note is $30,500 and $27,500, net of debt discount of $6,000 and $6,000, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payment of $1,000 due in March 2024. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the nine months ended September 30, 2019 was $1,587 and $6,667. Amortization for the debt discount and original issuance discount was $10,378 and $15,500, respectively for the nine months ended September 30, 2018. As of September 30, 2019 and December 31, 2018, the amount due is $60,000 and $61,746, net of discount of $0 and $8,254. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note was further restated in February 2021 and is due in August 2021(See Note 12). ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. 1,500,000 shares of common stock were issued due to the default of repayments with a fair value of $2,250 in 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At September 30, 2019 and December 31, 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 during 2018. At September 30, 2019 and December 31, 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. (3) At September 30, 2019 and December 31, 2018, the balance of $819,226 and $751,955 net of discount of $0 and $29,371, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At September 30, 2019 and December 31, 2018, the convertible note payable was recorded at $76,076 and $75,126, net of discount of $0 and $950, respectively. The accrued interest as of September 30, 2019 and December 31, 2018 is $12,150 and $8,177. During January and July 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated and was due January 2021. The Note was further restated in February 2021 and is due in August 2021(See Note 12). ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 during 2018. At September 30, 2019 and December 31, 2018, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. These Notes are in default and in negotiation of settlement. During the first quarter of 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. In addition, upon the issuance of convertible notes, the Company granted the total of 110,000,000 warrants at an exercise price of $0.001 per share. The warrants were valued at $8,147 using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further amended in December 2019, and August and October 2020. In connection with the issuance of amended convertible notes, the Company granted additional warrants at an exercise price of $0.001 per share (see Note 12). They are in default and in negotiation of settlement. During the second quarter of 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During the third quarter of 2019, repayment of $1,500 was made to one of the Notes. Amortization for the nine months ended September 30, 2019 and 2018 was $49,772 and $232,000. Amortization for the three months ended September 30, 2019 and 2018 was $6,714 and $88,887. At September 30, 2019 and December 31, 2018, the principal balance of the notes, net of discount of $0 and $28,421 is $683,150 and $589,829. (4) At September 30, 2019 and December 31, 2018, the balance of $3,069,656(net of discount of $33,516) and $1,156,341, respectively, consisted of the following convertible loans: ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carried interest at 12% and matured on September 8, 2017. The Note holder had the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019 (See Note 7). The new note of $49,819 carries interest at 8% and was due on February 13, 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During September 2018, the Noteholder made conversions of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $34,819 plus accrued interest, at fair value, was recorded at $107,602 and $62,508. ● During February 2018, we issued a convertible debenture in the amount of $200,000 to an unrelated third party. The note carried interest at 8% and was due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $200,000 plus accrued interest, at fair value, was recorded at $615,288 and $358,665. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carried interest at 8% and was due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $65,000 plus accrued interest, at fair value, was recorded at $199,969 and $115,165. ● During March 2018, we issued a convertible debenture in the amount of $60,000 to an unrelated third party. The note carried interest at 8% and was due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $60,000 plus accrued interest, at fair value, was recorded at $181,824 and $107,329. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. ● During June 2018, the $60,000 Back-end Note was funded. The note carried interest at 8% and was due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $60,000 plus accrued interest, at fair value, was recorded at $181,825 and $105,334. ● During May 2018, we issued a convertible debenture in the amount of $60,000 to an unrelated third party. The note carried interest at 8% and was due in May 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $60,000 plus accrued interest, at fair value, was recorded at $175,611 and $106,681. ● During August 2018, we issued a convertible debenture in the amount of $31,500 to an unrelated third party. The note carried interest at 8% and was due in August 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $31,500 plus accrued interest, at fair value, was recorded at $87,018 and $55,409. All of the above convertible notes with principal balance of a total of $511,319 were settled in October 2020 (See Note 12). ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carried interest at 8% and was due on May 4, 2018. We have accrued interest at default interest rate

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Deficit	7 . STOCKHOLDERS’ DEFICIT Common Stock Issued for Accrued Expense During January 2019, in connection with the settlement of a default penalty of debt of $110,000 originated in December 2016, we issued a total of 81,000,000 shares of our restricted common stock with a fair value of $32,400 to the Note holder (See Note 6). We had an accrual of $32,400 to account for the cost of the shares at December 31, 2018. Common Stock Issued for Services During June 2018, the Company signed an agreement with a consultant for investor relation services for twelve months. In connection with the agreement, 100,000,000 shares of the Company’s restricted common stocks were issued. The shares were valued at $0.0012 per share. The Company recorded an equity compensation charge of $30,000 and $40,000 during the three and nine months ended September 30, 2018. The Company recorded an equity compensation charge of $30,000 and $50,000 during the three and nine months ended September 30, 2019. During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 shares of our restricted common stock were issued. The shares were valued at $24,000. During June 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 15,000,000 shares of our restricted common stock were issued. The shares were valued at $6,000. The Company recorded an equity compensation charge of $7,500 and $14,000 during the three and nine months ended September 30, 2019. The remaining unrecognized compensation cost of $16,000 will be recognized by the Company over the remaining service period. Common Stock Issued with Indebtedness In May 2019, in connection with amendment of two convertible notes payable, we issued a total of 6,000,001 shares of our common stock with a fair value of $1,800 (See Note 6). In June 2019, in connection with issuance of a convertible notes payable, we issued a total of 16,000,000 shares of our common stock with a fair value of $4,688 (See Note 6). In September 2019, in connection with amendment of a promissory notes payable, we issued 20,000,000 shares of our common stock with a fair value of $5,895 (See Note 6). Common Stock Issued for Conversion of Debt During May and June 2019, the Note holder made conversions of a total of 750,000,000 shares of stock for a fair value of $275,000 satisfying the principal balance of $100,000 of a $219,879 Note originated in February 2019 (See Note 6). Number of Fair Value of Date shares converted Debt Converted 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000 Common Stock Issued for Debt Modification During May and June 2019, we issued a total of 3,500,000 restricted shares to three Note holders due to the default on repayment of the convertible notes. The shares were valued at fair value of $1,050. During July through September 2019, we issued a total of 18,500,000 restricted shares to five Note holders due to the default on repayment of the convertible notes. The shares were valued at fair value of $6,650.

Stock Warrants

Stock Warrants	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock Warrants	8. STOCK WARRANTS Common Stock Warrants During March, 2013, the Company issued a total of 65,000 warrants to purchase common stock at an exercise price of $0.01 per share in connection with issuance of a convertible note payable to Coventry. The warrants expired on March 22, 2018. On September 3, 2013 and September 12, 2013, the Company issued 500,000 and 375,000 warrants, respectively, to purchase common stock at an exercise price of $0.025 and $0.01 per share in connection with issuances of convertible notes payable to Coventry. The warrants expired on September 3, 2018 and September, 12, 2018, respectively. On March 31, 2017, in connection with the issuance of an $80,000 Note, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $632 and $977 using the Black-Scholes method on September 30, 2019 and December 31, 2018. The warrants expire on March 30, 2020. On March 3, 2016, in connection with the issuance of a convertible note, we granted five-year warrants to purchase an aggregate of 2,500,000 shares of our common stock at an exercise price of $0.03 per share. The warrants were valued at their fair value of $539 and $491 using the Black-Scholes method at September 30, 2019 and December 31, 2018. The warrants expire on March 3, 2021. On April 4, 2016, in connection with the issuance of convertible notes, we granted three-year warrants to purchase an aggregate of 4,000,000 shares of our common stock at an exercise price of $0.05 per share. The warrants were valued at their fair value of $0 using the Black-Scholes method at December 31, 2018. The warrants expired on April 4, 2019. During April, 2014, the Company issued a total of 100,000 warrants to purchase common stock at an exercise price of $0.025 per share in connection with issuance of a convertible note payable to Coventry. The warrants were valued at their fair value of $0 using the Black-Scholes method at December 31, 2018. The warrants expired on April 9, 2019. During February 2019, the Company granted the total of 110,000,000 warrants to purchase common stock at an exercise price of $0.001 per share in connection with issuance of three convertible notes. The warrants were valued at $8,147 using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The warrants expired in August 2019. A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the nine months ended September 30, 2019 and the year ended December 31, 2018: Number Of shares Weighted average exercise price Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - - Forfeited (940,000 ) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 110,000,000 0.001 Forfeited (114,100,000 ) 0.003 Balance September 30, 2019 8,500,000 $ 0.01 The following table summarizes information about fixed-price warrants outstanding as of September 30, 2019 and December 31, 2018 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price September 30, 2019 $ 0.005-0.03 8,500,000 0.77 years $ 0.01 December 31, 2018 $ 0.005-0.05 12,600,000 1.11 years $ 0.026 At September 30, 2019, the aggregate intrinsic value of all warrants outstanding and expected to vest was $0. The intrinsic value of warrant share is the difference between the fair value of our restricted common stock and the exercise price of such warrant share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money warrants had they exercised their warrants on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0003, the closing stock price of our restricted common stock on September 30, 2019. There were no in-the-money warrants at September 30, 2019.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Accrued Expenses	9. ACCRUED EXPENSES Accrued expenses consisted of the following: September 30, 2019 December 31, 2018 Accrued consulting fees $ 210,150 $ 161,550 Accrued settlement expenses 315,000 347,400 Accrued payroll taxes 156,000 120,182 Accrued interest 198,197 180,509 Accrued others 17,869 22,208 Total $ 897,216 $ 831,849

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	10. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consist of the following: September 30, December 31, Supplier advances for future purchases $ 233,759 $ 200,911 Reserve for supplier advances (200,911 ) (200,911 ) Net supplier advances 32,848 - Prepaid professional fees - 13,000 Deferred stock compensation 16,000 50,000 Total $ 48,848 $ 63,000 We performed an evaluation of our inventory and related accounts at September 30, 2019 and December 31, 2018, and increased the reserve on supplier advances for future venom purchases by $0 and $47,757, respectively. At September 30, 2019 and December 31, 2018, the total valuation allowance for prepaid venom is $200,911.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into our current three-year operating lease for monthly payments of approximately $3,200 which expired in February 2019. The lease is currently month-to-month, thus classified as short-term and not reported on the balance sheet under ASC 842. ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. September 30, 2019 Lease cost Operating lease cost $ 60,643 Short-term lease cost 51,135 Total lease cost $ 111,778 Balance sheet information Operating ROU Assets $ 220,532 Operating lease obligations, current portion 71,013 Operating lease obligations, non-current portion 162,679 Total operating lease obligations $ 233,692 Weighted average remaining lease term (in years) – operating leases 2.92 Weighted average discount rate-operating leases 8 % Supplemental cash flow information related to leases were as follows, for the nine months ended September 30, 2019: Cash paid for amounts included in the measurement of operating lease liabilities $ 53,605 Future minimum payments under these lease agreements are as follows: September 30, Total 2020 $ 87,161 2021 90,508 2022 85,628 Total future lease payments $ 263,297 Less imputed interest 29,605 Total $ 233,692 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. As the services provided were in dispute, the shares and note payable have not been issued as of September 30, 2019. We have accrued the $142,500 in accrued expense as of September 30, 2019 and December 31, 2018. During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 shares of the Company’s restricted common stock were granted and the Company was to make monthly cash payments of $3,000. As of December 31, 2016, the Company recorded an equity compensation charge of $31,750, however, only 1,000,000 of the shares have been issued. As of September 30, 2019 and December 31, 2018, $19,050 has been recorded in accrued expense to account for the 1,500,000 shares of common stock that have not been issued. Litigation Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. On June 1, 2015, ReceptoPharm entered into a settlement agreement with Patricia Meding, a former officer and shareholder of ReceptoPharm. The settlement relates to a lawsuit filed by Ms. Meding against ReceptoPharm (Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06, New York Supreme Court, Queens County) in which she claimed to own certain shares of ReceptoPharm stock and claimed to be owed amounts on a series of promissory notes allegedly executed in 2001 and 2002. The settlement agreement executed on June 1, 2015 provides that ReceptoPharm will pay Ms. Meding a total of $360,000 over 35 months. The first payment of $20,000 was made on July 1, 2015. A second payment of $20,000 was made on August 17, 2015 with 32 subsequent monthly $10,000 payments due on the 15th of every month thereafter. To date, ReceptoPharm has made all monthly payments due under the agreement. In the event of default on any of the payments due under the settlement agreement, the settlement amount would increase by an additional $200,000. As of December 31, 2018, all payments were made and the settlement is concluded. We have recorded $200,000 in gain on settlement of debt on the consolidated statements of operations upon payments in full in April 2018. Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and Receptopharm to recover $315,000 allegedly owing to them under a settlement agreement reached in an involuntary bankruptcy action that was brought by the same individuals in 2012 and for payment of unpaid wages/breach of written debt confirms. Nutra Pharma and Receptopharm believe that the lawsuit is without merit, especially in light of gross misconduct by these former employees that was discovered after execution of the aforementioned settlement agreement. On October 9, 2020, the Court entered an Order denying the plaintiffs’ motion for summary judgment with respect to Count I of the Complaint (for alleged breach of the aforementioned settlement agreement), and the parties continue to engage in discovery regarding their respective claims and defenses. The case is currently set for trial during the period from May 10, 2021 to May 28, 2021, but it is unclear at this time with the ongoing COVID-19 pandemic (and the resultant cessation of jury trials in Broward County) whether the trial will proceed at that time. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against the Company and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. Counsel for Get Credit Healthy, Inc. requested an early mediation conference in an attempt to resolve our dispute. We agreed to this request, and mediation took place on February 15, 2019. At December 31, 2018, we owed principal balance of $101,818 and accrued interest of $21,023. At mediation, Get Credit Healthy, Inc. claimed that the individual that breached the binding memorandum of understanding with the Company was never an owner of Get Credit Healthy, Inc., but rather, a close friend that encouraged Get Credit Healthy, Inc. to make the subject loan to the Company. Ultimately, the parties were able to reach a Confidential Settlement Agreement to resolve the dispute, and an Agreed Order was entered dismissing the lawsuit. The lawsuit was settled on February 15, 2019 for $104,000 with scheduled payments. The repayments were made in full as of November 2020 (See Note 6). CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note (contrary to the Get Credit Healthy lawsuit discussed above, we are certain that this individual is the majority owner of CSA 8411, LLC). Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At September 30, 2019, we owed principal balance of $91,156 and accrued interest of $27,191 (See Note 6) if the defenses and our new claims are deemed to be of no merit. The Company also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion is due May 3, 2021, and the Plaintiffs’ Reply Brief is due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On March 24, 2021, the Court entered an order granting the Motion for Extension of Time and modified the briefing schedule as follows: Plaintiffs’ Motion was filed on April 9, 2021, the Defendants’ Response was filed on May 7, 2021, and the Plaintiffs’ Reply is due on or before May 21, 2021. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	12. SUBSEQUENT EVENTS Convertible Notes Payable The convertible promissory notes to unrelated third parties for a total of $55,000 with original issuance discount of $5,000 issued in February 2019 were due in August 2019. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. During August 2020, $38,500 of the Notes was amended with additional original issuance discount of $7,550 due February 2021. During October 2020, $16,500 of the Notes was amended with additional original issuance discount of $1,650 due April 2021.The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0005. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. No warrants have been exercised. Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration December, 2019 44,000,000 7,370 August, 2020 August, 2020 92,100,000 22,879 August, 2021 October, 2020 39,930,000 9,497 October, 2022 During January 2020 through February 2020, the Note holder received a total of 500,000,000 shares of our restricted common stock in satisfaction the $175,000 of the Note with a fair value of $425,000. During February through April 2021, the Note holder received a total of 232,150,000 shares of our restricted common stock in satisfaction the $116,075 of the Note with a fair value of $2,362,552. The remaining balance of $5,838 is due September 2022. Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 150,000 2/18/2020 250,000,000 275,000 2/25/2021 137,700,000 1,500,930 3/3/2021 67,380,000 599,682 4/26/2021 27,070,000 261,940 During November 2019, we issued a convertible promissory note to an unrelated third party for $137,500 with original issuance discount of $12,500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.000275. The Note is in default and negotiation of settlement. During December 2019, we issued a convertible promissory note to an unrelated third party for $22,000 with original issuance discount of $2,000. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature (BCF) in the amount of $20,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During January and March 2020, we issued convertible promissory notes to an unrelated third party for a total of $68,750 with original issuance discount of $6,250. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $5,500. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Notes were due in January and March 2021. The Notes are in default and negotiation of settlement. During February and March 2020, we issued convertible promissory notes to an unrelated third party for a total of $22,000 with original issuance discount of $2,000. The notes were due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0003. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $20,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Notes are in default and negotiation of settlement. During March 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $5,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During March 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $3,300. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During August 2020, we issued a convertible promissory note to an unrelated third party for a $22,000 with original issuance discount of $2,000. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $13,200. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note is due August 2021. During July 2020, we issued a convertible promissory note to an unrelated third party for $20,900 with original issuance discount of $1,900. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00052. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $15,273. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note was due January 2021. The Note is in default and negotiation of settlement. During August 2020, we issued convertible promissory notes to an unrelated third party for $5,500 with original issuance discount of $500. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $1,100. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note was due February 2021. The Note is in default and negotiation of settlement. During November 2020, the Note holder assigned $20,000 of the $75,900 convertible note restated in January 2019 to a third party. The third party subsequently received a total of 100,000,000 shares of our restricted common stock in satisfaction the $20,000 of the Note with a fair value of $120,000. PPP Loan During May 2020, we entered into a long-term loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $64,895 with an annual interest rate of one percent (1%), with a term of twenty-four (24) months, whereby a portion of the loan proceeds have been used for certain labor costs, office rent costs and utilities, which may be subject to a loan forgiveness, pursuant to the terms of the SBA/PPP program. Economic Injury Disaster Loan During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $154,900, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due twelve months from the date of the SBA Loan Agreement in the amount of $731. The balance of principal and interest is payable over a 360 month period from the date of the SBA Loan Agreement. In connection therewith, the Company received a $5,000 advance, which does not have to be repaid. The SBA requires that the Company collateralize the loan to the maximum extent up to the loan amount. If business fixed assets do not “fully secure” the loan the lender may include trading assets (using 10% of current book value for the calculation), and must take available equity in the personal real estate (residential and investment) of the principals as collateral. Restatement of Promissory Notes During January 2020, the Note of $60,000 with original issuance discount of $10,000 amended in November 2018 and the Note of $88,225 plus accrued interest at a rate of 2.5% monthly to an unrelated third party were combined and restated. The restated principal balance was $148,225 that carries interest at a rate of 2.0% monthly due July 2020. During July 2020, the restated Note of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance was $166,926 that carries interest at a rate of 2.0% monthly and was due January 2021. During February 2021, we issued 29,072,500 shares of common stock to satisfy the accrued interest of $23,258 with fair value of $343,056. The settlement of accrued interest resulted in a loss on settlement of debt in other income for $319,798. The principal balance of $166,926 was further restated. The restated balance is $183,619 with an original issuance discount of $16,693 and is due August 2021. Settlement of Convertible Promissory Notes During December 2019, two Notes for a total of $9,900 with original issuance discount of $900 originated in February 2018 were settled with 40,000,000 shares of common stocks. The shares were valued at fair value of $24,000. During December 2019, three Notes for a total of $49,684 with original issuance discount of $2,700 originated in May 2017, January and September 2018, respectively, were settled with 260,000,000 shares of common stocks. The shares were valued at fair value of $130,000. During December 2019, two Notes for a total of $46,500 originated in October and November 2018 and the accounts payable of $39,000 for consulting fees were settled with 500,000,000 shares of common stocks. The shares were valued at fair value of $300,000, and have not been issued. During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes on September 30, 2019 was $511,319. During September 2020, a Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345. During October 2020, the Note holder sold the remaining debt of $467,000 and accrued interest of $166,168 for $250,000 to a non-related party. Number of Fair Value of Date shares converted Debt Converted 9/22/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 64,691 During April 2021, in connection with this settlement of the remaining balance of $8,500 of the Note of $12,000 originated in December 2018, we issued 2,000,000 shares of common stocks in satisfaction of $4,000 of the Note with a fair value of $15,200 and made a repayment of $4,500 in cash. Settlement and Restatement of Promissory Notes During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. Settlement of a Related-Party Note During June 2020, the Note of $14,400 with original issuance discount of $2,400 to a related party amended in December 2018 was settled with cash payment of $14,400 and 5,000,000 shares of common stocks. The shares were valued at fair value of $3,000. Advances During the periods from October 2019 through May 2020, the Company received a total of $175,000 in deposits from a third party in connection with a Joint Venture proposal. The deposits were considered as payments towards the purchase of equity in the joint venture. The joint venture is currently on hold pending the outcome of the lawsuit with the SEC. Common Stock Issued for Default Payments During January 2020, we issued a total of 75,000,000 restricted shares to a Note holder due to the default on repayments of the convertible promissory note of a total of $148,225 amended in August and November 2018. The shares were valued at fair value of $45,000. During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700. During September 2020, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $333,543 plus accrued interest amended in September 2019. The shares were valued at fair value of $6,000. During October 2020, we issued a total of 1,500,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $84,000 amended in March 2020. The shares were valued at fair value of $900. During January 2021, we issued a total of 25,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $166,926 amended in July 2020. The shares were valued at fair value of $107,500.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Organization	Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ®
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Reclassification occurred to certain prior year amounts in order to conform to the current year classifications. The reclassifications have no effect on the reported net loss.
Restatement of Prior Period Presentation	Restatement of Prior Period Presentation Certain prior period amounts have been restated. Restatements have been made for the three and nine months ended September 30, 2018 to correct the change in the fair value of convertible notes and to record a gain on settlement of debt and accounts payable. As a result of these changes, the following occurred: 1. Net loss for the three and nine months ended September 30, 2018 decreased by $0 and $3,110,017, respectively ($0.00 per share) (see table below). 2. At September 30, 2018, there was no change to total stockholders’ deficit but additional paid-in capital and accumulated deficit decreased by $3,110,017. 3. Certain amounts in cash flows from operating activities were updated for the nine months ended September 30, 2018, but there was no change to the total net cash used in operating activities in the Unaudited Condensed Consolidated Statements of Cash Flows. For the Nine Months Ended September 30, 2018 Amounts Restated Amounts Previously Reported Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (1,790,064 ) $ (4,151,435 ) $ 2,361,371 Gain(loss) on settlement of debt and accounts payable 728,223 (20,423 ) 748,646 Net effect of restatement on net loss $ 3,110,017
Liquidity and Going Concern	Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $63,828,564 at September 30, 2019. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $7,727,677 and a stockholders’ deficit of $8,126,685 at September 30, 2019. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Impact of COVID-19 on our Operations	Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895 (See Note 12). During April and June 2020, we obtained a loan in the amount of $154,900 from the SBA under its Economic Injury Disaster Loan assistance program. We intended to use the proceeds primarily for working capital purpose (See Note 12). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the development of widespread testing or a vaccine.
Use of Estimates	Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and warrant liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue from Contracts with Customers	Revenue from Contracts with Customers On January 1, 2018, we adopted Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon delivery of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor.
Accounting for Shipping and Handling Costs	Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record shipping and handling costs incurred within revenue.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivables. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. Management believes that the receivables are fully collectable. Therefore, no allowance for doubtful account was deemed to be required at September 30, 2019 and December 31, 2018.
Inventories	Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at September 30, 2019 and December 31, 2018, and increased the reserve on supplier advances for future venom purchases included in the prepaid expenses and other current assets by $0 and $47,757, respectively. At September 30, 2019 and December 31, 2018, the total valuation allowance for prepaid venom is $200,911.
Financial Instruments and Concentration of Credit Risk	Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended September 30, 2019, there were two customers that accounted for 62% and 13% of the total revenues. For the three months ended September 30, 2018, there was one customer that accounted for 35% of the total revenues. For the nine months ended September 30, 2019, there were two customers that accounted for 14% and 55% of the total revenues. For the nine months ended September 30, 2018, there was one customer that accounted for 27% of the total revenues. As of September 30, 2019 and December 31, 2018, 68% and 84% of the accounts receivable balance are reserves due from two payment processors.
Operating Lease Right-of-Use Asset and Liability	Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” (Topic 842), as amended (“ASC Topic 842”). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC Topic 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC Topic 842), therefore there was no change in accounting treatment required. For comparability purposes, the Company will continue to comply with the previous disclosure requirements in accordance with the existing lease guidance and prior periods are not restated. The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. For periods prior to the adoption of ASC Topic 842, the Company recorded rent expense based on the term of the related lease. The expense recognition for operating leases under ASC Topic 842 is substantially consistent with prior guidance. As a result, there are no significant differences in our results of operations presented. The impact of the adoption of ASC 842 on the balance sheet was: As reported December 31, 2018 Adoption of ASC 842 - increase (decrease) Balance January 1, 2019 Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592
Derivative Financial Instruments	Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Convertible Debt	Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.
The Fair Value Measurement Option	The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging
Property and Equipment and Long-Lived Assets	Property and Equipment and Long-Lived Assets Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.
Income Taxes	Income Taxes The Company recorded no income tax expense for the nine months ended September 30, 2019 and 2018 because the estimated annual effective tax rate was zero. As of September 30, 2019, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation
Net Loss Per Share	Net Loss Per Share Net loss per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share September 30, 2019 September 30, 2018 Options and warrants 8,500,000 12,600,000 Convertible notes payable 10,215,644,748 3,260,602,785 Total 10,224,144,748 3,273,202,785
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of Restatement of Prior Period Presentation	For the Nine Months Ended September 30, 2018 Amounts Restated Amounts Previously Reported Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (1,790,064 ) $ (4,151,435 ) $ 2,361,371 Gain(loss) on settlement of debt and accounts payable 728,223 (20,423 ) 748,646 Net effect of restatement on net loss $ 3,110,017
Schedule of impact of the adoption of ASC 842	The impact of the adoption of ASC 842 on the balance sheet was: As reported December 31, 2018 Adoption of ASC 842 - increase (decrease) Balance January 1, 2019 Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share	As of September 30, 2019 and 2018, the following items were not included in dilutive loss as the effect is anti-dilutive: September 30, 2019 September 30, 2018 Options and warrants 8,500,000 12,600,000 Convertible notes payable 10,215,644,748 3,260,602,785 Total 10,224,144,748 3,273,202,785

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Summary of Financial Instruments Measured at Fair Value	The following table summarizes our financial instruments measured at fair value at September 30, 2019 and December 31, 2018: Fair Value Measurements at September 30, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,171 $ - $ - $ 1,171 Convertible notes at fair value $ 3,103,172 $ - $ - $ 3,103,172 Fair Value Measurements at December 31, 2018 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,468 $ - $ - $ 1,468 Convertible notes at fair value $ 1,156,341 $ - $ - $ 1,156,341
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs	The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the nine months ended September 30, 2019 and the year ended December 31, 2018: Description September 30, 2019 December 31, 2018 Beginning balance $ 1,468 $ 5,903 Total gain included in earnings (1) (297 ) (4,435 ) Ending balance $ 1,171 $ 1,468 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.
Convertible Notes Payable [Member]
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs	The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2019 and the year ended December 31, 2018: Description September 30, 2019 December 31, 2018 Beginning balance $ 1,156,341 $ 1,925,959 Purchases and issuances 629,183 472,029 Day one loss on value of hybrid instrument (1) 788,230 2,021,041 Loss from change in fair value (1) 804,418 130,344 Gain on settlement - (958,581 ) Conversion to common stock (275,000 ) (2,434,451 ) Ending balance $ 3,103,172 $ 1,156,341 (1) The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.
Summary of Assumptions and the Significant Terms	The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at September 30, 2019 and December 31, 2018: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Conversion Price % of stock price for look-back period Look-back September 30, 2019 $ 1,159,883 8%-20% 20%-24% 15.95-27.95 $0.00012-$0.000165 50%-60% 3 to 25 Days December 31, 2018 $ 1,340,026 8%-12% 18%-20% 25.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	At September 30, 2019 and December 31, 2018, inventories were as follows: September 30, 2019 December 31, 2018 Raw Materials $ 34,433 $ 33,431 Finished Goods 1,796 1,871 Total Inventories $ 36,229 $ 35,302

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following at September 30, 2019 and December 31, 2018: September 30, 2019 December 31, 2018 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (208,558 ) (205,533 ) Property and equipment, net $ 7,475 $ 10,500

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Debt	Debts consist of the following at September 30, 2019 and December 31, 2018: September 30, 2019 December 31, 2018 Note payable– Related Party (Net of discount of $600 and $2,400, $ 13,800 $ 12,000 Notes payable – Unrelated third parties (Net of discount of $11,895 1,411,308 1,469,690 Convertible notes payable – Unrelated third parties (Net of discount of 819,226 751,955 Convertible notes payable, at fair value (Net of discount of $33,516 and $0, respectively) (4) 3,069,656 1,156,341 Ending balances 5,313,990 3,389,986 Less: Long-term portion-Notes payable-Unrelated third parties $ (- ) $ (51,410 ) Less: Long-term portion-Convertible Notes payable-Unrelated third parties (479,886 ) - Current portion $ 4,834,104 $ 3,338,576 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At September 30, 2019 and December 31, 2018, we owed this director accrued interest of $154,871 and $141,808. The interest expense for the nine-months ended September 30, 2019 and 2018 was $13,063 and $11,609, respectively, and $4,499 and $3,998 for the three-months ended September 30, 2019 and 2018, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At September 30, 2019 and December 31, 2018, the principal balance of the loan was $13,800 and $12,000, net of debt discount of $600 and $2,400, respectively. The Note was settled in June 2020. (2) At September 30, 2019 and December 31, 2018, the balance of $1,411,308 and $1,469,690 net of discount of $11,895 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At September 30, 2019 and December 31, 2018, we owed principal balance of $168,135 and $192,974, and accrued interest of $48,213 and $40,033, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 11) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At September 30, 2019 and December 31, 2018, the accrued interest is $3,499 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At September 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $46,901 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At September 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $40,100 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018.The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. The note is in default and negotiation of settlement. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the nine months ended September 30, 2019 and 2018 was $3,616 and $2,765, respectively. The debt discount at September 30, 2019 and December 31, 2018 is $0 and $3,616. During September 2019, the Notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,895(See Note 7) and recorded as a debt discount that was amortized over the life of the note. The Note is in default and negotiation of settlement. At September 30, 2019 and December 31, 2018, the principal balance is $333,543 and $282,983, and the accrued interest is $4,670 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In January 2019, the principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). The remaining note of $15,000 was assigned to an unrelated third party and is in negotiation of settlement. At September 30, 2019 and December 31, 2018, the principal balance is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At September 30, 2019 and December 31, 2018, the accrued interest is $36,400 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At September 30, 2019 and December 31, 2018, the accrued interest is $2,892 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively. The monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid a total of $34,976 during the year ended 2018 and $23,080 during the nine months ended September 30, 2019. At September 30, 2019 and December 31, 2018, the principal balance is $112,346 and $135,426. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At September 30, 2019 and December 31, 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the nine months ended September 30, 2019 and 2018 was $6,000 and $6,000, respectively. The debt discount at September 30, 2019 and December 31, 2018 is $6,000 and $6,000, respectively. Repayments of $1,500 and $7,000 have been made during 2017 and 2018, respectively. During the nine months ended September 30, 2019, repayment of $3,000 has been made. The Note is under personal guarantee by Mr. Deitsch. At September 30, 2019 and December 31, 2018, the principal balance of the note is $30,500 and $27,500, net of debt discount of $6,000 and $6,000, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payment of $1,000 due in March 2024. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the nine months ended September 30, 2019 was $1,587 and $6,667. Amortization for the debt discount and original issuance discount was $10,378 and $15,500, respectively for the nine months ended September 30, 2018. As of September 30, 2019 and December 31, 2018, the amount due is $60,000 and $61,746, net of discount of $0 and $8,254. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note was further restated in February 2021 and is due in August 2021(See Note 12). ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. 1,500,000 shares of common stock were issued due to the default of repayments with a fair value of $2,250 in 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At September 30, 2019 and December 31, 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 during 2018. At September 30, 2019 and December 31, 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. (3) At September 30, 2019 and December 31, 2018, the balance of $819,226 and $751,955 net of discount of $0 and $29,371, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At September 30, 2019 and December 31, 2018, the convertible note payable was recorded at $76,076 and $75,126, net of discount of $0 and $950, respectively. The accrued interest as of September 30, 2019 and December 31, 2018 is $12,150 and $8,177. During January and July 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated and was due January 2021. The Note was further restated in February 2021 and is due in August 2021(See Note 12). ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 during 2018. At September 30, 2019 and December 31, 2018, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. These Notes are in default and in negotiation of settlement. During the first quarter of 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. In addition, upon the issuance of convertible notes, the Company granted the total of 110,000,000 warrants at an exercise price of $0.001 per share. The warrants were valued at $8,147 using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further amended in December 2019, and August and October 2020. In connection with the issuance of amended convertible notes, the Company granted additional warrants at an exercise price of $0.001 per share (see Note 12). They are in default and in negotiation of settlement. During the second quarter of 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During the third quarter of 2019, repayment of $1,500 was made to one of the Notes. Amortization for the nine months ended September 30, 2019 and 2018 was $49,772 and $232,000. Amortization for the three months ended September 30, 2019 and 2018 was $6,714 and $88,887. At September 30, 2019 and December 31, 2018, the principal balance of the notes, net of discount of $0 and $28,421 is $683,150 and $589,829. (4) At September 30, 2019 and December 31, 2018, the balance of $3,069,656(net of discount of $33,516) and $1,156,341, respectively, consisted of the following convertible loans: ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carried interest at 12% and matured on September 8, 2017. The Note holder had the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019 (See Note 7). The new note of $49,819 carries interest at 8% and was due on February 13, 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During September 2018, the Noteholder made conversions of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $34,819 plus accrued interest, at fair value, was recorded at $107,602 and $62,508. ● During February 2018, we issued a convertible debenture in the amount of $200,000 to an unrelated third party. The note carried interest at 8% and was due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $200,000 plus accrued interest, at fair value, was recorded at $615,288 and $358,665. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carried interest at 8% and was due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $65,000 plus accrued interest, at fair value, was recorded at $199,969 and $115,165. ● During March 2018, we issued a convertible debenture in the amount of $60,000 to an unrelated third party. The note carried interest at 8% and was due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $60,000 plus accrued interest, at fair value, was recorded at $181,824 and $107,329. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. ● During June 2018, the $60,000 Back-end Note was funded. The note carried interest at 8% and was due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $60,000 plus accrued interest, at fair value, was recorded at $181,825 and $105,334. ● During May 2018, we issued a convertible debenture in the amount of $60,000 to an unrelated third party. The note carried interest at 8% and was due in May 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $60,000 plus accrued interest, at fair value, was recorded at $175,611 and $106,681. ● During August 2018, we issued a convertible debenture in the amount of $31,500 to an unrelated third party. The note carried interest at 8% and was due in August 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At September 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $31,500 plus accrued interest, at fair value, was recorded at $87,018 and $55,409. All of the above convertible notes with principal balance of a total of $511,319 were settled in October 2020 (See Note 12). ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carried interest at 8% and was due on May 4, 2018. We have accrued interest at default interest rate of 20% af

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000

Stock Warrants (Tables)

Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Summary of Warrants Outstanding	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the nine months ended September 30, 2019 and the year ended December 31, 2018: Number Of shares Weighted average exercise price Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - - Forfeited (940,000 ) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 110,000,000 0.001 Forfeited (114,100,000 ) 0.003 Balance September 30, 2019 8,500,000 $ 0.01
Summary of Fixed Price Warrants Outstanding	The following table summarizes information about fixed-price warrants outstanding as of September 30, 2019 and December 31, 2018 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price September 30, 2019 $ 0.005-0.03 8,500,000 0.77 years $ 0.01 December 31, 2018 $ 0.005-0.05 12,600,000 1.11 years $ 0.026

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: September 30, 2019 December 31, 2018 Accrued consulting fees $ 210,150 $ 161,550 Accrued settlement expenses 315,000 347,400 Accrued payroll taxes 156,000 120,182 Accrued interest 198,197 180,509 Accrued others 17,869 22,208 Total $ 897,216 $ 831,849

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: September 30, December 31, Supplier advances for future purchases $ 233,759 $ 200,911 Reserve for supplier advances (200,911 ) (200,911 ) Net supplier advances 32,848 - Prepaid professional fees - 13,000 Deferred stock compensation 16,000 50,000 Total $ 48,848 $ 63,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Cost and Balance Sheet Information	September 30, 2019 Lease cost Operating lease cost $ 60,643 Short-term lease cost 51,135 Total lease cost $ 111,778 Balance sheet information Operating ROU Assets $ 220,532 Operating lease obligations, current portion 71,013 Operating lease obligations, non-current portion 162,679 Total operating lease obligations $ 233,692 Weighted average remaining lease term (in years) – operating leases 2.92 Weighted average discount rate-operating leases 8 % Supplemental cash flow information related to leases were as follows, for the nine months ended September 30, 2019: Cash paid for amounts included in the measurement of operating lease liabilities $ 53,605
Schedule of Future Minimum Payments Under These Lease Agreements	Future minimum payments under these lease agreements are as follows: September 30, Total 2020 $ 87,161 2021 90,508 2022 85,628 Total future lease payments $ 263,297 Less imputed interest 29,605 Total $ 233,692

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2019
Summary of Warrants Outstanding	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the nine months ended September 30, 2019 and the year ended December 31, 2018: Number Of shares Weighted average exercise price Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - - Forfeited (940,000 ) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 110,000,000 0.001 Forfeited (114,100,000 ) 0.003 Balance September 30, 2019 8,500,000 $ 0.01
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 5/6/2019 250,000,000 $ 75,000 5/31/2019 250,000,000 $ 100,000 6/6/2019 250,000,000 $ 100,000
Convertible Notes Payable [Member]
Summary of Warrants Outstanding	Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration December, 2019 44,000,000 7,370 August, 2020 August, 2020 92,100,000 22,879 August, 2021 October, 2020 39,930,000 9,497 October, 2022
Schedule of Common Stock Issued for Conversion of Debt	Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 150,000 2/18/2020 250,000,000 275,000 2/25/2021 137,700,000 1,500,930 3/3/2021 67,380,000 599,682 4/26/2021 27,070,000 261,940 Number of Fair Value of Date shares converted Debt Converted 9/22/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 64,691

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	May 31, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2017
Net loss			$ (487,072)	$ (967,915)	$ (2,555,722)	$ (3,296,244)
Accumulated deficit			(63,828,564)		(63,828,564)		$ (61,272,842)
Working capital deficit			(7,727,677)		(7,727,677)
Stockholders' deficit			(8,126,685)	(5,364,923)	(8,126,685)	(5,364,923)	(5,936,593)	$ (7,652,158)	$ (5,104,837)	$ (5,410,194)
Net sales			41,962	$ 43,966	93,499	$ 104,323
Reserve on supplier advances			0		0		47,757
Inventory adjustments			$ 200,911		$ 200,911		$ 200,911
Minimum [Member]
Property and equipment estimated useful lives					3 years
Maximum [Member]
Property and equipment estimated useful lives					7 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration risk, percentage			62.00%	35.00%	14.00%	27.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration risk, percentage			13.00%		55.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration risk, percentage					68.00%		84.00%
ASC Topic 606 [Member]
Net sales				$ 960		$ 3,740
Subsequent Event [Member] | PPP [Member]
Proceeds form loan	$ 64,895	$ 154,900

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Restatement of Prior Period Presentation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Change in fair value of convertible notes and derivatives	$ 187,823	$ (192,800)	$ 1,592,351	$ 1,790,064
Gain (loss) on settlement of debt and accounts payable				728,223
Net effect of restatement on net loss	$ (487,072)	$ (967,915)	$ (2,555,722)	(3,296,244)
Amounts Previously Reported [Member]
Change in fair value of convertible notes and derivatives				(4,151,435)
Gain (loss) on settlement of debt and accounts payable				(20,423)
Adjustments Decrease in Net Loss [Member]
Change in fair value of convertible notes and derivatives				2,361,371
Gain (loss) on settlement of debt and accounts payable				748,646
Net effect of restatement on net loss				$ 3,110,017

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of impact of the adoption of ASC 842 (Details) - USD ($)	Sep. 30, 2019	Jan. 02, 2019	Dec. 31, 2018
Operating lease right-of-assets	$ 220,532	$ 281,175
Total assets	370,386	422,592	141,417
Operating lease liabilities, current portion	71,013	64,573
Operating lease liabilities, net of current portion	162,679	216,602
Total liabilities		6,359,185	6,078,010
Total liabilities and stockholders' equity	$ 370,386	$ 422,592	141,417
Adoption of ASC 842 - Increase (Decrease) [Member]
Operating lease right-of-assets			281,175
Total assets			281,175
Operating lease liabilities, current portion			64,573
Operating lease liabilities, net of current portion			216,602
Total liabilities			281,175
Total liabilities and stockholders' equity			$ 281,175

Basis of Presentation and Sum_7

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive securities excluded from computation of earnings per share	10,224,144,748	3,273,202,785
Option and Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	8,500,000	12,600,000
Convertible Debt Securities [Member]
Antidilutive securities excluded from computation of earnings per share	10,215,644,748	3,260,602,785

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative)	Sep. 30, 2019
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants outstanding, measurement input	1.75
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants outstanding, measurement input	2.81
Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrants outstanding, measurement input	256
Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrants outstanding, measurement input	335

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Warrant liability	$ 1,171	$ 1,468
Convertible notes at fair value	3,103,172	1,156,341
Fair Value, Inputs, Level 1 [Member]
Warrant liability	1,171	1,468
Convertible notes at fair value	3,103,172	1,156,341
Fair Value, Inputs, Level 2 [Member]
Warrant liability
Convertible notes at fair value
Fair Value, Inputs, Level 3 [Member]
Warrant liability
Convertible notes at fair value

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2019	Dec. 31, 2018
Convertible Notes Payable [Member]
Beginning balance		$ 1,156,341	$ 1,925,959
Purchases and issuances		629,183	472,029
Day one loss on value of hybrid instrument		788,230	2,021,041
Loss from change in fair value		804,418	130,344
Gain on settlement			(958,581)
Conversion to common stock		(275,000)	(2,434,451)
Ending balance			1,156,341
Warrant [Member]
Beginning balance		1,468	5,903
Total gain included in earnings	[1]	(297)	(4,435)
Ending balance		$ 1,171	$ 1,468
[1]	The gain related to the revaluation of our warrant liability is included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations.

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Assumptions and the Significant Terms (Details) - Convertible Notes Payable [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2019d$ / shares	Dec. 31, 2018d$ / shares
Minimum [Member]
Conversion Price | $ / shares	$ .00012	$ .0002
Percentage of stock price for look-back period	50.00%	40.00%
Look-back period | d	3	3
Maximum [Member]
Conversion Price | $ / shares	$ .000165	$ .20
Percentage of stock price for look-back period	60.00%	60.00%
Look-back period | d	25	25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Long-term debt, measurement input	8	8
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Long-term debt, measurement input	20	12
Measurement Input, Default Interest Rate [Member] | Minimum [Member]
Long-term debt, measurement input	20	18
Measurement Input, Default Interest Rate [Member] | Maximum [Member]
Long-term debt, measurement input	24	20
Measurement Input, Discount Rate [Member] | Minimum [Member]
Long-term debt, measurement input	15.95	25.95
Measurement Input, Discount Rate [Member] | Maximum [Member]
Long-term debt, measurement input	27.95	27.95

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw Materials	$ 34,433	$ 33,431
Finished Goods	1,796	1,871
Total Inventories	$ 36,229	$ 35,302

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation	$ 815	$ 1,105	$ 3,025	$ 4,858

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property and equipment, gross	$ 216,033	$ 216,033
Less: Accumulated depreciation	(208,558)	(205,533)
Property and equipment, net	7,475	10,500
Computer Equipment [Member]
Property and equipment, gross	25,120	25,120
Furniture and Fixtures [Member]
Property and equipment, gross	34,757	34,757
Lab Equipment [Member]
Property and equipment, gross	53,711	53,711
Office Equipment - Other [Member]
Property and equipment, gross	12,421	16,856
Telephone Equipment [Member]
Property and equipment, gross	16,856	12,421
Leasehold Improvements [Member]
Property and equipment, gross	$ 73,168	$ 73,168

Due to_from Officer (Details Na

Due to/from Officer (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Due to officer	$ 139,722		$ 186,497
Repayment of officers loans	94,765	$ 141,070
Loans from officer	5,000	107,100
Accrued interest expense for amount due to officer	4,990
Company other receivable	543,470		$ 505,470
Rik Deitsch [Member]
Due to officer	$ 139,722	$ 186,497
Bears interest percentage	4.00%	4.00%
Repayment of officers loans	$ 94,765	$ 141,070
Loans from officer	5,000	107,100
Accrued interest expense for amount due to officer	4,990	$ 7,674
Due to advance	$ 38,000

Debts (Details)

Debts (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Note payable- Related Party -Net of discount of $600 and $2,400, respectively) -1)	$ 13,800	$ 12,000
Notes payable - Unrelated third parties -Net of discount of $11,895 and $17,870, respectively) -2)	1,411,308	1,469,690
Convertible notes payable - Unrelated third parties -Net of discount of $0 and $29,371, respectively) -3)	819,226	751,955
Convertible notes payable, at fair value -Net of discount of $33,516 and $0, respectively) -4)	3,069,656	1,156,341
Ending balances	5,313,990	3,389,986
Less: Long-term portion-Notes payable-Unrelated third parties		(51,410)
Less: Long-term portion-Convertible Notes payable-Unrelated third parties	(479,886)
Current portion	$ 4,834,104	$ 3,338,576

Debts (Details) (Parentheticals

Debts (Details) (Parentheticals) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Related Party [Member]
Debt discount	$ 6,000	$ 2,400
Non Related Party [Member]
Debt discount	11,895	17,870
Non Related Parties Convertible Notes Payable [Member]
Debt discount	0	29,371
Convertible Notes Payable [Member]
Debt discount	$ 33,516	$ 0

Debt (Details1)

Debt (Details1)	Jul. 31, 2020USD ($)	Jun. 06, 2019shares	May 31, 2019USD ($)shares	May 06, 2019shares	Feb. 15, 2019USD ($)	Jan. 31, 2019USD ($)	Aug. 14, 2018USD ($)shares	Jul. 31, 2018USD ($)shares	Jun. 30, 2018USD ($)	Feb. 28, 2018USD ($)	Sep. 08, 2017d	Jul. 31, 2017USD ($)	Mar. 31, 2017USD ($)shares	Mar. 28, 2016USD ($)	Feb. 28, 2015USD ($)	Mar. 19, 2014USD ($)	Jun. 30, 2012USD ($)	Aug. 31, 2019USD ($)	Jan. 31, 2019USD ($)	Aug. 31, 2018USD ($)shares	Jun. 30, 2018USD ($)shares	Apr. 30, 2018USD ($)	Jun. 30, 2019USD ($)$ / sharesshares	Jul. 31, 2017USD ($)shares	Sep. 30, 2019USD ($)$ / sharesshares	Mar. 31, 2019USD ($)	Sep. 30, 2018USD ($)	Mar. 31, 2012USD ($)shares	Sep. 30, 2019USD ($)d$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)d$ / sharesshares	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)shares	Apr. 30, 2021USD ($)	Mar. 31, 2021USD ($)	Oct. 31, 2020USD ($)$ / shares	Sep. 30, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Jan. 31, 2020USD ($)	Jul. 31, 2019USD ($)	Jun. 17, 2019USD ($)shares	Feb. 28, 2019USD ($)$ / sharesshares	Oct. 31, 2018USD ($)	Jul. 12, 2018USD ($)	Mar. 18, 2018$ / shares	Nov. 30, 2017USD ($)shares	Oct. 31, 2017USD ($)shares	Oct. 20, 2017USD ($)	Oct. 12, 2017USD ($)	Sep. 30, 2017USD ($)$ / shares	Aug. 31, 2017	Jul. 26, 2017USD ($)$ / shares	Jun. 30, 2017USD ($)	May 31, 2017USD ($)	May 04, 2017	Feb. 28, 2017$ / shares	Jan. 31, 2017USD ($)	Oct. 31, 2016USD ($)	Sep. 26, 2016USD ($)	Aug. 31, 2016USD ($)shares	Jul. 31, 2016USD ($)$ / shares	May 31, 2016USD ($)	Apr. 30, 2016USD ($)	Apr. 30, 2014$ / shares	Sep. 12, 2013$ / sharesshares	Sep. 03, 2013$ / sharesshares	Aug. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Feb. 15, 2012USD ($)	Feb. 12, 2012USD ($)	Dec. 31, 2011USD ($)	Aug. 15, 2011USD ($)	Aug. 02, 2011USD ($)	Dec. 31, 2010USD ($)	Feb. 28, 2010	Jan. 31, 2010
Notes payable																									$ 5,313,990				$ 5,313,990			$ 3,389,986
Accrued interest																													27,191
Interest expense, debt																									52,918		$ 262,891		187,895	$ 695,763
Repayments of notes payable																													11,500	3,000
Gain loss on extinguishment of debt																									$ (6,650)		(40,100)		49,553	728,223
Debt instrument accrued interest																													$ 66,460
Common stock, shares, issued | shares																									5,076,746,111				5,076,746,111			4,046,746,110		1,000,000
Common stock issued value																									$ 5,076,746				$ 5,076,746			$ 4,046,746
Amortization of debt discount															$ 8,147														$ 81,564	314,219
Stock issued price per shares | $ / shares																									$ 0.18				$ 0.18
Debt conversion, converted instrument, shares issued | shares		250,000,000	250,000,000	250,000,000
Debt instrument conversion feature																														246,913
Number of warrants issued | shares																									65,000				65,000																																					375,000	500,000
Warrant exercise price | $ / shares																									$ 0.01				$ 0.01														$ 0.001																						$ 0.025	$ 0.01	$ 0.025
NonRelatedPartyFiveMember
Notes payable																																													$ 220,506
Debt instrument, interest rate, stated percentage																																													0.25%
Non Related Party Ten [Member]
Notes payable																																12,000
Non Related Party Sixteen [Member]
Debt instrument, interest rate, stated percentage																						24.00%
Convertible notes payable																						$ 65,000
Debt instrument convertible debt percentage																						8.00%
Settlement Agreement [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Cash settlement																																						$ 84,000
Promissory Note [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Common stock, shares, issued | shares																																							10,000,000
Common stock issued value																																							$ 41,000
Convertible Debtentures [Member] | Non Related Party Twelve [Member]
Convertible notes payable																$ 500,000																27,000											$ 1,000,000
Repayments of convertible debt																15,000																3,000
Debt instrument convertible debt percentage																																														8.00%
Stock issued price per shares | $ / shares																																														$ 0.20
Deposit liabilities, accrued interest																																11,412
Convertible Debtentures [Member] | Non Related Party Thirteen [Member]
Convertible notes payable																1,000,000
Repayments of convertible debt																$ 30,000
Convertible Debtentures [Member] | Non Related Party Fourteen [Member]
Notes payable										$ 65,600
Accrued interest																				$ 10,476
Debt instrument, unamortized discount net issuance costs							$ 1,035
Debt instrument, unamortized discount																				3,800					$ 0				$ 0			950
Amortization of debt discount																										$ 950						2,850
Convertible notes payable										$ 65,600										$ 76,076					76,076				76,076			75,126																					$ 56,567					$ 56,567				$ 50,000
Debt instrument convertible debt percentage										2.50%										2.50%																																						2.50%				2.00%
Stock issued price per shares | $ / shares																																																					$ 0.05									$ 0.05
Debt conversion, converted instrument, shares issued | shares							1,000,000													5,000,000
Convertible Debtentures [Member] | Settlement Agreement [Member] | Non Related Party Twelve [Member]
Cash settlement																																											$ 38,412
Back and End Note [Member] | Non Related Party Sixteen [Member]
Accrued interest																													181,824			107,329
Interest expense, debt																																60,000
Debt instrument accrued interest																						$ 100,000
Convertible notes payable																						110,700			65,000				65,000
Back and End Note [Member] | Non Related Party Seventeen [Member]
Debt instrument, interest rate, stated percentage									24.00%												24.00%
Accrued interest																													175,611	106,681
Convertible notes payable									$ 60,000												$ 60,000				60,000				60,000			60,000
Repayments of convertible debt																					$ 59,257
Debt instrument convertible debt percentage									8.00%												8.00%
Back and End Note [Member] | Non Related Party Eighteen [Member]
Debt instrument, interest rate, stated percentage																				24.00%
Convertible notes payable																				$ 31,500
Debt instrument convertible debt percentage																				8.00%
Deposit liabilities, accrued interest																									31,500				31,500
Convertible Notes Payable, Current																									87,018				87,018			55,409
Derivative loss																				$ 23,794
Note Payable One [Member]
Interest expense, debt																									4,499		3,998		13,063	11,609
Note Payable One [Member] | Promissory Note [Member]
Notes payable																									13,800				13,800			12,000	$ 12,000
Debt instrument, unamortized discount net issuance costs																									600				600			2,400	2,000
Note Payable One [Member] | Director [Member]
Notes payable																																																																											$ 200,000
Debt instrument, interest rate, stated percentage																																																																												12.00%	10.00%
Accrued interest																													154,871			141,808
Note Payable Two [Member]
Notes payable																									1,411,308				1,411,308			1,469,690
Debt instrument, unamortized discount net issuance costs																									11,895				11,895			17,870
Note Payable Two [Member] | Non Related Party [Member]
Notes payable																																																															$ 75,000
Debt instrument, interest rate, stated percentage																																																															2.00%
Repayments of notes payable																													50,000
Repayments of lines of credit																													40,100			31,000
Note Payable Two [Member] | UniversityCentreWestLtdMember
Debt instrument rent expenses																																																																					$ 55,410
Note Payable Two [Member] | Non Related Party [Member]
Notes payable																																																	$ 180,250
Debt instrument, interest rate, stated percentage																																																	2.50%
Note Payable Two [Member] | NonRelatedPartyFiveMember
Notes payable												$ 200,000												$ 200,000
Debt instrument, interest rate, stated percentage																																																				15.00%
Debt issuance costs, gross												5,500												5,500
Note Payable Two [Member] | Non Related Party Two [Member]
Accrued interest																																282,983
Debt instrument, unamortized discount net issuance costs																									0				0			3,616
Common stock, shares, issued | shares																																										10,000,000
Debt instrument, unamortized discount																																										$ 3,945
Amortization of debt discount																													3,616			2,765
Note Payable Two [Member] | Non Related Party Two [Member] | Subsequent Event [Member]
Notes payable																																						$ 333,543
Common stock, shares, issued | shares																																						333,543
Debt instrument, unamortized discount																																						$ 5,895
Note Payable Two [Member] | Non Related Party Eight [Member]
Notes payable																																																			$ 1,000
Debt instrument, interest rate, stated percentage																																																			12.00%
Debt instrument, unamortized discount net issuance costs																									6,000				6,000			6,000
Debt instrument convertible price per share | $ / shares																																																			$ 0.01
Repayments of notes payable																														3,000		7,000	1,500
Note Payable Two [Member] | Non Related Party Nine [Member]
Debt instrument, unamortized discount net issuance costs																						10,000																			$ 10,000
Note Payable Two [Member] | Non Related Party Nine [Member] | Minimum [Member]
Debt instrument, unamortized discount net issuance costs																									60,000		0		60,000	0
Amortization of debt discount																															$ 1,587	10,378
Note Payable Two [Member] | Non Related Party Nine [Member] | Maximum [Member]
Debt instrument, unamortized discount net issuance costs																									61,746		8,254		61,746	8,254
Amortization of debt discount																															6,667	$ 15,500
Long-term debt, maturities																				$ 76,076
Note Payable Two [Member] | Non Related Party Ten [Member]
Notes payable																									120,000				120,000
Common stock, shares, issued | shares													125,000,000																			1,500,000
Common stock issued value													$ 119,700																			$ 2,250
Note Payable Two [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Notes payable																																							50,000
Debt instrument, unamortized discount net issuance costs																																							120,000
Debt instrument, unamortized discount																																							$ 20,000
Note Payable Two [Member] | Non Related Party Eleven [Member]
Notes payable																																															$ 18,000
Debt instrument, unamortized discount net issuance costs																																															$ 3,000
Note Payable Two [Member] | Liquid Packaging Resources Inc [Member]
Non-payment penalty charges																												$ 100,000
Note Payable Two [Member] | Southridge Partners, LLP [Member]
Notes payable																																																																				$ 281,772
Noncash transaction, value consideration received																	$ 281,772
Note Payable Two [Member] | Settlement Agreement [Member] | NonRelatedPartyFiveMember
Notes payable																																	191,329
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Two [Member]
Notes payable																									333,543				333,543			282,983
Accrued interest																													4,670			2,830
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Four [Member]
Accrued interest																													2,892			1,944
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member]
Notes payable																									112,346				112,346			135,426
Repayments of notes payable									$ 130,401																				23,080			$ 34,976
Repayments of lines of credit									40,000
Cash settlement									20,927												$ 20,927
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member] | Subsequent Event [Member]
Repayments of notes payable	$ 5,000
Repayments of lines of credit	2,000
Outstanding notes payable																																			$ 33,874
Cash settlement																																			$ 130,401
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Nine [Member]
Common stock, shares, issued | shares																																10,000,000
Common stock issued value																																$ 3,000
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Eleven [Member]
Accrued interest																													2,000			0
Repayments of notes payable																													5,600			18,000
Common stock, shares, issued | shares																																															7,000,000
Note Payable Two [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Notes payable																																																																						$ 50,000	$ 50,000		$ 50,000	$ 350,000
Repayments of lines of credit																												$ 25,000
Debt principal amount																																																																								$ 175,000
Non-payment penalty charges																																																																								$ 25,000
Sale of stock, number of shares | shares																												142,858
Note Payable Two [Member] | Promissory Note [Member]
Notes payable																																																																$ 10,000
Debt instrument, interest rate, stated percentage																																																																10.00%
Debt instrument accrued interest																													3,499			2,739
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party [Member]
Notes payable																																																													$ 150,000
Debt instrument, interest rate, stated percentage																																																													2.50%
Note Payable Two [Member] | Promissory Note [Member] | NonRelatedPartyOneMember
Notes payable																																										$ 282,983
Debt instrument, interest rate, stated percentage																																										2.00%
Repayments of notes payable								$ 220,506
Common stock, shares, issued | shares								5,000,000																																																					2,000,000
Common stock issued value								$ 5,500
Debt instrument, unamortized discount																																																													$ 2,765
Amortization of debt discount																																2,765
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Three [Member]
Notes payable						60,000													$ 60,000						15,000				15,000			75,000																												$ 75,000
Debt instrument, interest rate, stated percentage																																																												10.00%
Accrued interest																													1,371			17,271
Debt instrument accrued interest																			15,900
Long-term debt, maturities						15,000													15,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Four [Member]
Notes payable																																																											$ 50,000
Debt instrument, interest rate, stated percentage																																																											2.00%
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Seven [Member]
Notes payable												50,000												50,000	50,000				50,000			50,000
Amortization of debt discount												$ 10,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member]
Notes payable																																																			$ 36,000
Debt instrument, unamortized discount net issuance costs																									6,000		6,000		6,000	6,000																					$ 6,000
Amortization of debt discount																													6,000	6,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member] | Subsequent Event [Member]
Notes payable																																				$ 33,000
Debt instrument, unamortized discount net issuance costs																																				$ 3,000		$ 6,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Nine [Member]
Notes payable																																	60,000															$ 50,000
Debt instrument, unamortized discount net issuance costs																																																$ 10,000
Common stock, shares, issued | shares																																																5,000,000
Debt instrument, unamortized discount																																																$ 3,200
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Ten [Member]
Notes payable																																															$ 120,000
Debt instrument, unamortized discount net issuance costs																																															$ 20,000
Common stock, shares, issued | shares																																															10,000,000
Debt instrument, unamortized discount																																															$ 5,600
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Ten [Member] | Subsequent Event [Member]
Common stock, shares, issued | shares																																							36,000,000
Common stock issued value																																							$ 70,000
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eleven [Member]
Debt default, amount																																															$ 29,000
Common stock, shares, issued | shares																																															5,000,000
Note Payable Two [Member] | Promissory Note Two [Member]
Notes payable					$ 101,818																				98,000				98,000																					$ 201,818
Debt instrument, interest rate, stated percentage																																																		12.00%
Accrued interest					21,023																								21,023
Debt instrument convertible price per share | $ / shares																																																									$ 0.008
Repayments of notes payable													$ 6,365
Repayments of lines of credit					$ 104,000																								6,000
Gain loss on extinguishment of debt																													18,841
Outstanding notes payable																									91,156				91,156
Note Payable Two [Member] | Promissory Note Two [Member] | Settlement [Member]
Repayments of lines of credit																													27,191
Note Payable Two [Member] | Reverse Stock Split [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Non-payment penalty charges																												$ 350,000
Sale of stock, number of shares | shares																												5,714,326
Cash settlement																												$ 4,500,000
Debt default, amount																												$ 1,000,000
Note Payable Two [Member] | Note Holder [Member] | Non Related Party Nine [Member]
Debt instrument, unamortized discount net issuance costs			$ 10,000																																									$ 10,000
Debt default, amount			$ 2,381
Common stock, shares, issued | shares			5,000,000
Common stock issued value																						$ 60,000
Note Payable Two [Member] | Director [Member] | Promissory Note Two [Member]
Notes payable																									168,135				168,135			192,974																						$ 8,844							$ 200,000
Debt instrument, interest rate, stated percentage																																																													12.00%
Accrued interest																															48,213	40,033
Note Payable Two [Member] | Former Director [Member] | Promissory Note Two [Member]
Notes payable																																																													$ 100,000
Note Payable Two [Member] | Mr. Deitsch [Member] | Non Related Party Eight [Member]
Notes payable																									30,500				30,500			27,500
Debt instrument, unamortized discount net issuance costs																									6,000				6,000			6,000
Outstanding notes payable																									30,000				30,000
Convertible Notes Payable [Member]
Notes payable																									819,223				819,223			751,955
Debt instrument, unamortized discount net issuance costs																									0				0		5,000	29,371
Debt instrument, unamortized discount																									33,516				33,516			$ 0
Amortization of debt discount																		$ 8,200							683,150		589,829		0	28,421
Convertible notes payable																															$ 70,000
Number of warrants issued | shares																															110,000,000
Warrant exercise price | $ / shares																															$ 0.001
Warrant outstanding																															$ 8,147
Amortization																									$ 6,714		88,887		$ 49,772	232,000
Convertible Notes Payable [Member] | Warrant [Member]
Warrant exercise price | $ / shares																															$ 0.001
Convertible Notes Payable [Member] | Common Stock [Member]
Debt instrument, unamortized discount net issuance costs																															$ 6,400
Common stock, shares, issued | shares																															6,000,001
Common stock issued value																															$ 1,800
Convertible Notes Payable [Member] | Minimum [Member]
Debt instrument convertible price per share | $ / shares																									$ .00012				$ .00012			$ .0002
Trading days | d																													3			3
Convertible Notes Payable [Member] | Maximum [Member]
Debt instrument convertible price per share | $ / shares																									$ .000165				$ .000165			$ .20
Trading days | d																													25			25
Convertible Notes Payable [Member] | Subsequent Event [Member]
Convertible notes payable																																					$ 511,319
Convertible Notes Payable [Member] | Subsequent Event [Member] | Warrant [Member]
Warrant exercise price | $ / shares																																					$ 0.001
Convertible Notes Payable [Member] | Non Related Party Fourteen [Member]
Accrued interest																													$ 12,150			$ 8,177
Convertible Notes Payable [Member] | Non Related Party Fourteen [Member] | Subsequent Event [Member]
Convertible notes payable	$ 60,000																																							$ 60,000
Convertible Notes Payable [Member] | Non Related Party Fifteen [Member]
Debt instrument, unamortized discount net issuance costs																																																10,000
Debt default, amount																																																$ 3,300
Common stock, shares, issued | shares																																																5,000,000
Convertible notes payable																																																$ 60,000
Convertible Notes Payable [Member] | Non Related Party Twenty [Member]
Debt instrument, unamortized discount net issuance costs																																$ 62,950
Common stock, shares, issued | shares																																10,250,000
Common stock issued value																																$ 6,542
Debt instrument, unamortized discount																																255,655
Amortization of debt discount																																62,950
Convertible notes payable																																$ 618,250
Debt conversion, converted instrument, shares issued | shares																																249,113
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Minimum [Member]
Debt instrument convertible debt percentage																																0.03%
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Maximum [Member]
Debt instrument convertible debt percentage																																0.10%
Convertible Notes Payable [Member] | Non Related Party Nighteen [Member]
Accrued interest										$ 63,144
Non-payment penalty charges										12,442																																					$ 6,400
Convertible notes payable																									$ 105,988				105,988			$ 63,315	185,765														856								$ 64,000
Debt instrument convertible debt percentage																																																								8.00%
Deposit liabilities, accrued interest									$ 8,607												$ 8,607				34,060				34,060			8,607															$ 21,399
Debt conversion, converted instrument, shares issued | shares																					50,670,000
Debt instrument conversion feature																					$ 70,938								29,381
Convertible Notes Payable [Member] | Non Related Party Twenty One[Member]
Convertible notes payable								$ 50,000																	153,909				153,909
Debt instrument convertible debt percentage								8.00%
Convertible Notes Payable, Current																																96,157
Derivative loss								$ 46,734
Convertible Notes Payable [Member] | Non Related Party Twenty Two[Member]
Debt instrument convertible debt percentage																				8.00%
Convertible Notes Payable, Current																				$ 20,000					45,204				45,204			$ 38,297
Derivative loss																				$ 17,829
Convertible Notes Payable [Member] | Non Related Party Twenty Three [Member]
Convertible notes payable						60,000													60,000
Convertible Notes Payable [Member] | Non Related Party Twenty Four [Member]
Convertible notes payable																									213,283				213,283
Deposit liabilities, accrued interest																									479,886				479,886
Convertible Notes Payable [Member] | Brewer and Associates Consulting, LLC [Member] | Non Related Party Twenty [Member]
Repayments of notes payable																																	60,000	$ 40,000
Convertible notes payable														$ 120,000											58,273		$ 47,481		58,273	$ 47,481			20,000
Extinguishment debt extinguishment assets payments														7,000
Derivative, collateral, obligation to return cash														$ 36,000
Convertible Notes Payable [Member] | Promissory Note [Member] | Non Related Party Twenty Three [Member]
Convertible notes payable						75,000													75,000						170,775				170,775
Deposit liabilities, accrued interest						15,900													15,900
Convertible Notes Payable [Member] | Promissory Note [Member] | Non Related Party Twenty Four [Member]
Notes payable																									313,283				313,283
Debt instrument accrued interest																													11,412
Repayments of convertible debt																													27,000
Debt conversion, converted instrument, shares issued | shares																							750,000,000
Debt instrument conversion feature																							$ 275,000
Number of warrants issued | shares																																											1,000,000
Warrant exercise price | $ / shares																																											$ 0.0005
Convertible Notes Payable, Current																							$ 100,000
Derivative loss																									$ 472,331				$ 472,331
Convertible Notes Payable [Member] | Promissory Note [Member] | Settlement Agreement [Member] | Non Related Party Fifteen [Member]
Common stock, shares, issued | shares																									1,000,000				1,000,000			1,000,000
Common stock issued value																									$ 1,500				$ 1,500			$ 1,500
Convertible notes payable																									60,000				60,000			60,000
Convertible Notes Payable [Member] | Note Holder [Member]
Repayments of convertible debt																															1,500
Convertible Notes Payable [Member] | Restatement Note [Member] | Non Related Party Twenty Three [Member]
Repayments of convertible debt																			75,900
Derivative loss						$ 75,900													$ 75,900
Convertible Notes Payable [Member] | Convertible Promissory Note [Member] | Non Related Party Twenty Five [Member]
Debt instrument convertible price per share | $ / shares																							$ 0.0005
Common stock, shares, issued | shares																							16,000,000
Common stock issued value																							$ 4,688
Debt instrument, unamortized discount																							40,000		33,516				33,516
Amortization of debt discount																													11,172
Convertible notes payable																							240,000		$ 540,000				540,000
Derivative loss																							$ 240,000
Convertible Notes Payable One [Member] | Non Related Party Sixteen [Member]
Debt instrument accrued interest																													200,000
Convertible Notes Payable One [Member] | Convertible Debtentures [Member]
Debt instrument, unamortized discount																															33,516
Convertible notes payable																															$ 3,069,656	1,156,341
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | Non Related Party Sixteen [Member]
Accrued interest																								$ 63,001
Common stock, shares, issued | shares								105,157,409
Common stock issued value								$ 147,220
Convertible notes payable										$ 200,000																						32,400		$ 110,000									$ 1,646,242
Debt instrument convertible debt percentage										8.00%	12.00%																																24.00%
Debt conversion, converted instrument, shares issued | shares																								179,800,000
Debt instrument conversion feature																								$ 298,575
Convertible Notes Payable, Current																																	$ 147,314
Trading days | d											60
Convertible Notes Payable One [Member] | Note Payable One [Member] | Non Related Party Sixteen [Member]
Debt instrument accrued interest																																615,288
Convertible Notes Payable One [Member] | Note Payable Two [Member] | Non Related Party Sixteen [Member]
Debt instrument accrued interest																													358,665
Convertible Notes Payable One [Member] | Note Payable Three [Member] | Non Related Party Sixteen [Member]
Accrued interest																																115,165
Debt instrument accrued interest																																$ 200,000
Convertible Notes Payable One [Member] | Back and End Note [Member] | Non Related Party Sixteen [Member]
Accrued interest																													199,969
Debt instrument accrued interest																													$ 100,000

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Sep. 30, 2019	Jun. 30, 2019	May 31, 2019	Jan. 31, 2019	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Apr. 30, 2019	Dec. 31, 2016
Debt conversion, original debt, amount				$ 110,000
Common stock shares issued	5,076,746,111					5,076,746,111		5,076,746,111		4,046,746,110		1,000,000
Common stock shares value	$ 5,076,746					$ 5,076,746		$ 5,076,746		$ 4,046,746
Debt instrument, convertible, beneficial conversion feature									$ 246,913
Common stock per share value	$ 0.001					$ 0.001		$ 0.001		$ 0.001
Equity compensation charge				$ 14,000		$ 7,500
Share-based payment arrangement, nonvested award, cost not yet recognized, amount	$ 16,000					16,000		$ 16,000
Stock issued during period, value, conversion of convertible securities	$ 20,000,000	$ 16,000,000	$ 6,000,001				$ 519,564	275,000	2,434,452
Stock issued during period, shares, conversion of convertible securities	5,895	4,688	1,800
Note holder [Member]
Debt conversion, original debt, amount		$ 100,000	$ 100,000
Stock issued during period, value, conversion of convertible securities		$ 750,000,000	$ 750,000,000
Stock issued during period, shares, conversion of convertible securities		275,000	275,000
Debt instrument, fair value disclosure		$ 21,987	$ 21,987
Consultant Agreement [Member]
Equity compensation charge						30,000	$ 30,000	$ 50,000	$ 40,000
Restricted Stock [Member]
Common stock shares issued		15,000,000		81,000,000							120,000,000
Common stock shares value		$ 6,000		$ 32,400							$ 24,000
Debt instrument, convertible, beneficial conversion feature										$ 32,400
Restricted Stock [Member] | Three note holder [Member]
Stock issued during period, value, conversion of convertible securities		$ 3,500,000	$ 3,500,000			$ 18,500,000
Stock issued during period, shares, conversion of convertible securities		1,050	1,050			6,650
Restricted Stock [Member] | Consultant Agreement [Member]
Stock issued during the period for services					100,000,000
Common stock per share value					$ 0.0012

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($)	Jun. 06, 2019	May 31, 2019	May 06, 2019
Equity [Abstract]
Number of shares converted	250,000,000	250,000,000	250,000,000
Fair value of debt converted	$ 100,000	$ 100,000	$ 75,000

Stock Warrants (Details Narrati

Stock Warrants (Details Narrative) - USD ($)	Mar. 31, 2017	Apr. 04, 2016	Mar. 03, 2016	Feb. 28, 2015	Apr. 30, 2014	Sep. 30, 2019	Sep. 30, 2018	Feb. 28, 2019	Dec. 31, 2018	Sep. 12, 2013	Sep. 03, 2013
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						65,000				375,000	500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.025	$ 0.01		$ 0.001		$ 0.01	$ 0.025
Warrants and Rights Outstanding, Maturity Date					Apr. 9, 2019	Mar. 22, 2018				Sep. 12, 2018	Sep. 3, 2018
Notes Payable						$ 5,313,990			$ 3,389,986
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares)				110,000,000	100,000
Warrants Not Settleable in Cash, Fair Value Disclosure									$ 0
Debt Discout				$ 8,147		$ 81,564	$ 314,219
Common Stock, Par or Stated Value Per Share						$ 0.001			$ 0.001
Three Year Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.005	$ 0.05
Warrants and Rights Outstanding, Maturity Date	Mar. 30, 2020	Apr. 4, 2019
Notes Payable	$ 80,000
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares)	600,000	4,000,000
Warrants Not Settleable in Cash, Fair Value Disclosure						$ 632			$ 977
Three Year Warrant [Member] | Convertible Debt Securities [Member]
Warrants Not Settleable in Cash, Fair Value Disclosure									0
Five Year Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.03
Warrants and Rights Outstanding, Maturity Date			Mar. 3, 2021
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares)			2,500,000
Warrants Not Settleable in Cash, Fair Value Disclosure						539			$ 491
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Nonvested						$ 0
Common Stock, Par or Stated Value Per Share						$ 0.0003

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued consulting fees	$ 210,150	$ 161,550
Accrued settlement expenses	315,000	347,400
Accrued payroll taxes	156,000	120,182
Accrued interest	198,197	180,509
Accrued others	17,869	2,208
Total	$ 897,216	$ 831,849

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details Narrative) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Future reserve for purchases	$ 0	$ 47,757
Total valuation allowance for prepaid	$ 200,911	$ 200,911

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Supplier advances for future purchases	$ 233,759	$ 200,911
Reserve for supplier advances	(200,911)	(200,911)
Net supplier advances	32,848
Prepaid professional fees		13,000
Deferred stock compensation	16,000	50,000
Total	$ 48,848	$ 63,000

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)

Feb. 15, 2019

Dec. 31, 2018

Oct. 12, 2018

Aug. 01, 2017

Jul. 31, 2017

Aug. 31, 2016

Feb. 28, 2016

Oct. 30, 2015

Aug. 17, 2015

Jun. 01, 2015

Sep. 30, 2019

Sep. 30, 2018

Jun. 30, 2019

Apr. 30, 2019

Jan. 31, 2019

Dec. 31, 2016

Operating lease term

3 years

Operating lease due

$ 3,200

Lease expiration date

Feb. 28, 2019

Common stock shares issued

4,046,746,110

5,076,746,111

1,000,000

Note issued

$ 32,400

$ 348,050

Shares issued, price per share

$ 0.18

Accrued liabilities for commissions, expense and taxes

$ 142,500

Equity compensation charges

$ 31,750

Accrued expenses

$ 19,050

Share based compensation, shares not yet issued

1,500,000

Litigation term payment

$ 20,000

$ 20,000

Litigation term description

The first payment of $20,000 was made on July 1, 2015. A second payment of $20,000 was made on August 17, 2015 with 32 subsequent monthly $10,000 payments due on the 15th of every month thereafter.

Payment in event of default

200,000

Gain (loss) related to litigation settlement

200,000

Notes payable

$ 3,389,986

5,313,990

Accrued interest

$ 27,191

Loss contingency, allegations

The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief.

Restricted Stock [Member]

Common stock shares issued

15,000,000

120,000,000

81,000,000

Consulting Services Agreement [Member] | Restricted Stock [Member]

Consulting service term

5 years

Common stock shares issued

500,000

Debt instrument, interest rate,

8.00%

Note issued

$ 50,000

Consultant Agreement [Member]

Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted

2,500,000

Consultant Agreement [Member] | Common Stock [Member]

Debt instrument periodic payment

$ 3,000

Recepto Pharm Leases [Member]

Operating lease due

$ 6,900

Lease, description

ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year.

Patricia Meding [Member]

Litigation settlement, amount awarded to other party

$ 360,000

Litigation settlement term of payments

35 months

Paul Reid et al[Member]

Loss contingency, damages sought, value

$ 315,000

Get Credit Healthy, Inc. and Rik Deitsch,[Member]

Loss contingency, damages sought, value

$ 100,000

Long-term debt

$ 101,818

$ 21,023

Payments for legal settlements

$ 104,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Lease Cost and Balance Sheet Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Jan. 02, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 60,643
Short-term lease cost	51,135
Total lease cost	111,778
Operating ROU Assets	220,532	$ 281,175
Operating lease obligations, current portion	71,013	64,573
Operating lease obligations, non-current portion	162,679	$ 216,602
Total operating lease obligations	$ 233,692
Weighted average remaining lease term (in years) - operating leases	2 years 11 months 1 day
Weighted average discount rate-operating leases	8.00%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 53,605

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Future Minimum Payments Under These Lease Agreements (Details) - USD ($)	Sep. 30, 2019	Feb. 28, 2016
Total future lease payments		$ 3,200
Total	$ 233,692
Lease Agreements [Member]
2020	87,161
2021	90,508
2022	85,628
Total future lease payments	263,297
Less imputed interest	29,605
Total	$ 233,692

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 31, 2020	Jan. 31, 2019	Nov. 30, 2017	Apr. 30, 2021	Feb. 28, 2021	Jan. 31, 2021	Nov. 30, 2020	Oct. 31, 2020	Sep. 30, 2020	Aug. 31, 2020	Jul. 31, 2020	Jun. 30, 2020	Jun. 30, 2020	May 31, 2020	Apr. 30, 2020	Apr. 30, 2020	Mar. 31, 2020	Feb. 28, 2020	Jan. 31, 2020	Dec. 31, 2019	Dec. 31, 2019	Feb. 28, 2019	Feb. 28, 2018	Feb. 29, 2020	Apr. 30, 2021	May 31, 2020	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Nov. 30, 2019	Jun. 30, 2019	May 31, 2019	Nov. 30, 2018	Oct. 31, 2018	Jan. 31, 2018	May 31, 2017	Apr. 30, 2014	Sep. 12, 2013	Sep. 03, 2013
Warrants exercise price																						$ 0.001					$ 0.01										$ 0.025	$ 0.01	$ 0.025
Debt instrument, convertible, beneficial conversion feature																												$ 246,913
Debt instrument, accrued interest																											$ 66,460
Restricted Stock [Member]
Debt instrument, convertible, beneficial conversion feature																													$ 32,400
Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount																							$ 9,900				511,319	49,684	12,000				$ 46,500	$ 46,500	$ 49,684	$ 49,684
Debt instrument, original discount																							$ 900					$ 2,700							$ 2,700	$ 2,700
Number of shares issued																							40,000,000
Number of shares issued, value																							$ 24,000
Settlement and Restatement of Promissory Notes[Member]
Debt instrument, face amount			$ 20,000
Number of shares issued			125,000,000
Subsequent Event [Member] | Payroll Protection Program [Member] | Long-term Loan Agreement [Member]
Proceeds from loan														$ 64,895
Debt instrument, interest rate,														1.00%												1.00%
Debt instrument, term														24 months
Subsequent Event [Member] | Economic Injury Disaster Loan [Member] | SBA Loan Agreement [Member]
Debt instrument, face amount												$ 731	$ 731		$ 731	$ 731
Proceeds from loan												$ 5,000	$ 154,900		$ 5,000	$ 154,900
Debt instrument, interest rate,												3.75%	3.75%		3.75%	3.75%
Subsequent Event [Member] | Restatement of Promissory Notes [Member]
Debt instrument, face amount											$ 166,926
Debt instrument, due date											2021-01
Debt instrument, interest rate,											2.00%
Debt instrument, accrued interest					$ 23,258
Number of shares issued					29,072,500
Number of shares issued, value					$ 343,056
Other income					319,798
Subsequent Event [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount				$ 8,500																					$ 8,500
Debt instrument fair value				$ 15,200																					15,200
Debt instrument, accrued interest								$ 166,168
Number of shares issued				2,000,000																260,000,000	500,000,000
Number of shares issued, value				$ 4,000																$ 130,000	$ 300,000
Accounts payable																				$ 39,000	$ 39,000
Repayment of debt				4,500
Subsequent Event [Member] | Settlement and Restatement of Promissory Notes[Member]
Debt instrument, face amount																	$ 50,000
Debt instrument, original discount																	$ 120,000
Debt instrument, due date																	2020-09
Number of shares issued																	36,000,000
Debt instrument, debt default, amount																	$ 84,000
Subsequent Event [Member] | Restated [Member] | Restatement of Promissory Notes [Member]
Debt instrument, face amount					166,926						$ 148,225								$ 148,225
Debt instrument, original discount					$ 16,693
Debt instrument, due date					2021-08														2020-01
Debt instrument, interest rate,																			2.00%
Debt instrument, accrued interest											$ 18,701
Subsequent Event [Member] | Restated [Member] | Settlement and Restatement of Promissory Notes[Member]
Debt instrument, face amount																	70,000
Debt instrument, original discount																	$ 14,000
Subsequent Event [Member] | Adjustments Decrease in Net Loss [Member] | Settlement and Restatement of Promissory Notes[Member]
Number of shares issued																	10,000,000
Number of shares issued, value																	$ 119,700
Unrelated Third Parties [Member] | Subsequent Event [Member] | Restatement of Promissory Notes [Member]
Debt instrument, face amount																			$ 60,000
Debt instrument, original discount																			$ 10,000
Debt instrument, interest rate,																			2.50%
Debt instrument, accrued interest																			$ 88,225
Note Holder [Member]
Debt instrument fair value																															$ 21,987	$ 21,987
Note Holder [Member] | Subsequent Event [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, face amount								$ 22,000	$ 22,000
Stock issued during period, restricted stock								107,817,770	107,133,333
Debt instrument, accrued interest								$ 10,345	$ 10,140
Remaining debt sold								$ 467,000
Note Holder [Member] | Subsequent Event [Member] | Common Stock Issued for Default Payments [Member] | Restricted Stock [Member]
Stock issued during period, restricted stock						25,000,000		1,500,000	10,000,000		1,000,000								75,000,000
Stock issued during period, restricted stock value						$ 107,500		$ 900	$ 6,000		$ 700								$ 45,000
Repayments of convertible debt						$ 166,926		84,000	$ 333,543		22,000								148,225
Third Party [Member] | Subsequent Event [Member] | Advances [Member]
Proceeds from deposits																										$ 175,000
Non Related Party [Member] | Subsequent Event [Member] | Settlement of Convertible Promissory Notes [Member]
Debt instrument, accrued interest								$ 250,000
Related Party [Member] | Subsequent Event [Member] | Settlement of a Related-Party Note [Member]
Debt instrument, face amount												$ 14,400	$ 14,400
Debt instrument, original discount												$ 2,400	$ 2,400
Number of shares issued													5,000,000
Number of shares issued, value													$ 3,000
Repayment of debt													$ 14,400
Convertible Notes Payable [Member]
Debt instrument, original discount																											$ 33,516		$ 0
Warrants exercise price																				$ 0.001	$ 0.001
Convertible Notes Payable [Member] | Warrant [Member]
Warrants exercise price																				$ 0.001	$ 0.001
Convertible Notes Payable [Member] | Subsequent Event [Member] | Warrant [Member]
Warrants exercise price								$ 0.001
Convertible Notes Payable [Member] | Unrelated Third Parties [Member]
Debt instrument, face amount																						$ 55,000
Debt instrument, original discount																						$ 5,000
Debt instrument, due date																						2019-08
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Subsequent Event [Member]
Debt instrument, face amount								$ 16,500		$ 38,500	20,900						68,750	$ 22,000	68,750	$ 22,000	$ 22,000									$ 137,500
Debt instrument, original discount								$ 1,650		$ 7,550	$ 1,900						$ 6,250	$ 2,000	$ 6,250	$ 2,000	$ 2,000									$ 12,500
Debt instrument, due date								2021-04		2021-02										2020-06
Convertible Notes Payable [Member] | Note Holder [Member] | Subsequent Event [Member]
Debt instrument, face amount				5,838			$ 20,000																		$ 5,838
Debt instrument, due date											2021-01														2022-09
Debt conversion price								$ 0.0005			$ 0.00052						$ 0.0005	$ 0.0003	$ 0.0005	$ 0.0002	$ 0.0002									$ 0.000275
Stock issued during period, restricted stock																								500,000,000	232,150,000
Stock issued during period, restricted stock value																								$ 175,000	$ 116,075
Debt instrument fair value				$ 2,362,552			$ 120,000																	$ 425,000	$ 2,362,552
Debt instrument, convertible, beneficial conversion feature											$ 15,273						$ 5,500	$ 20,000	$ 5,500	$ 20,000
Convertible Notes Payable [Member] | Unrelated Third Parties One [Member] | Subsequent Event [Member]
Debt instrument, face amount										$ 22,000							22,000
Debt instrument, original discount										$ 2,000							$ 2,000
Convertible Notes Payable [Member] | Note Holder One [Member] | Subsequent Event [Member]
Debt instrument, due date										2021-08
Debt conversion price										$ 0.0005							$ 0.0003
Debt instrument, convertible, beneficial conversion feature										$ 13,200							$ 20,000
Convertible Notes Payable [Member] | Unrelated Third Parties Two [Member] | Subsequent Event [Member]
Debt instrument, face amount										5,500							5,500
Debt instrument, original discount										$ 500							$ 500
Convertible Notes Payable [Member] | Note Holder Two [Member] | Subsequent Event [Member]
Debt instrument, due date										2021-02
Debt conversion price										$ 0.0005							$ 0.0002
Debt instrument, convertible, beneficial conversion feature										$ 1,100							$ 5,000
Convertible Notes Payable [Member] | Unrelated Third Parties Three [Member] | Subsequent Event [Member]
Debt instrument, face amount																	5,500
Debt instrument, original discount																	$ 500
Convertible Notes Payable [Member] | Note Holder Three [Member] | Subsequent Event [Member]
Debt conversion price																	$ 0.0005
Debt instrument, convertible, beneficial conversion feature																	$ 3,300
Convertible Notes Payable [Member] | Third Party [Member] | Restated [Member]
Debt instrument, face amount		$ 75,900
Convertible Notes Payable [Member] | Third Party [Member] | Subsequent Event [Member]
Debt instrument, face amount	$ 55,900
Debt instrument, due date	2021-01
Stock issued during period, restricted stock							100,000,000
Stock issued during period, restricted stock value							$ 20,000

Subsequent Events - Summary of

Subsequent Events - Summary of Warrants Outstanding (Details) - USD ($)	Jun. 06, 2019	May 31, 2019	May 06, 2019	Feb. 28, 2015	Apr. 30, 2014	Oct. 31, 2020	Aug. 31, 2020	Dec. 31, 2019
Number of Warrants				110,000,000	100,000
Fair Value of Warrants	$ 100,000	$ 100,000	$ 75,000
Subsequent Event [Member] | Warrants [Member]
Number of Warrants						39,930,000	92,100,000	44,000,000
Fair Value of Warrants						$ 9,497	$ 22,879	$ 7,370
Month of Expiration						2022-10	2021-08	2020-08

Subsequent Events - Schedule of

Subsequent Events - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($)	Apr. 26, 2021	Feb. 25, 2021	Oct. 05, 2020	Sep. 22, 2020	Mar. 03, 2020	Feb. 18, 2020	Jan. 21, 2020	Jun. 06, 2019	May 31, 2019	May 06, 2019
Number of shares converted								250,000,000	250,000,000	250,000,000
Fair Value of Debt Converted								$ 100,000	$ 100,000	$ 75,000
Subsequent Event [Member] | Note Holder [Member]
Number of shares converted	27,070,000	137,700,000	107,817,770	107,133,333	67,380,000	250,000,000	250,000,000
Fair Value of Debt Converted	$ 261,940	$ 1,500,930	$ 64,691	$ 171,413	$ 599,682	$ 275,000	$ 150,000